No retraction, correction or concern found when last checked on Oct 24, 2026.

Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia

Mehdi Eshraghi, Aida Adlimoghaddam, Amir Mahmoodzadeh and 5 more

International Journal of Molecular Sciences · 2021 · Review · CC BY

doi:10.3390/ijms22073330

Abstract

Alzheimer’s disease (AD) is a debilitating neurological disorder, and currently, there is no cure for it. Several pathologic alterations have been described in the brain of AD patients, but the ultimate causative mechanisms of AD are still elusive. The classic hallmarks of AD, including amyloid plaques (Aβ) and tau tangles (tau), are the most studied features of AD. Unfortunately, all the efforts targeting these pathologies have failed to show the desired efficacy in AD patients so far. Neuroinflammation and impaired autophagy are two other main known pathologies in AD. It has been reported that these pathologies exist in AD brain long before the emergence of any clinical manifestation of AD. Microglia are the main inflammatory cells in the brain and are considered by many researchers as the next hope for finding a viable therapeutic target in AD. Interestingly, it appears that the autophagy and mitophagy are also changed in these cells in AD. Inside the cells, autophagy and inflammation interact in a bidirectional manner. In the current review, we briefly discussed an overview on autophagy and mitophagy in AD and then provided a comprehensive discussion on the role of these pathways in microglia and their involvement in AD pathogenesis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Alzheimer’s disease (AD) is a progressive neurodegenerative condition characterized by loss of memory and abnormal mood and behavior. Most cases of AD are sporadic and aging is the biggest risk factor for AD. The disease was first described by Dr. Alois Alzheimer in 1906; however, the fine structure of the pathologic hallmarks of AD (i.e., Aβ plaques and neurofibrillary tangles) were described by using electron microscopy in 1963. In recent decades, many therapeutic approaches that targeted Aβ and tau pathologies have failed to show the desirable efficacy for alleviating cognitive impairments in AD patients. Possible reasons for these failures may include: treating the patients during later stages of AD, targeting the wrong pathologic mechanism, and an insufficient understanding of the complex multifactorial nature of AD, which may require combination therapy over mono-therapy.

2However, recent studies suggest a critical role for microglia and neuroinflammation in AD. While under normal conditions, microglia’s main function is to support the integrity and survival of neuronal networks, in AD a special group of microglia (i.e., disease associated microglia or DAM) appear that seems to contribute to the aberrant neuroinflammation in the brain and consequent neurodegeneration. The focus of the current review is to survey the current knowledge about the role of microglia and neuroinflammation in AD. Specifically, we would like to emphasize the importance of a known but underrated pathology in AD, which is impaired autophagy and mitophagy. Impaired autophagy and mitophagy are present in the vast majority of AD cases. It is believed that Aβ/tau aggregation and impaired autophagy/mitophagy and neuroinflammation are intertwined processes and create several vicious cycles in the course of AD. In this review paper, first, we will discuss the current knowledge of impaired autophagy/mitophagy and neuroinflammation in AD. Next, we will provide evidence of the interplays between impaired autophagy/mitophagy and microglial over-activation/neuroinflammation in AD.

2. Alzheimer’s Disease; A Global Health Crisis

3Dementia has been classified as a neurocognitive disorder which presents with cognitive and/or behavioral impairments and are accompanied with a progressive need for support with activities of daily living (ADL). Dementia is an imminent global health crisis; approximately 50 million people are living with dementia worldwide. However, due to the rise of seniors among the global population and lack of an effective treatment, the number of individuals with dementia is growing significantly. This number is expected to increase considerably, reaching 152 million by 2050, a 204% increase. According to the World Health Organization (WHO), the global cost associated with healthcare related to dementia was 1% of the aggregated global gross domestic product (GDP), or 604 and 818 billion USD, in 2010 and 2015, respectively. Rising numbers of people with dementia will place greater demands on both formal care (e.g., residential facility, medication, hospitalization) and informal care (e.g., family members, friends, or neighbors). Therefore, dementia has a great effect not only on individuals with the disease, but also on their families and friends.

4AD is the most common form of dementia; it accounts for 60–80% of all dementia cases. According to the WHO, AD was the fifth leading cause of global death in 2016. Currently, there is no cure for AD; however, some pharmacological therapeutics can delay the progression of the disease and/or alleviate some symptoms of AD. Typically, physicians recommend various options for AD treatment based on the severity of the disease. The AD severity is categorized into mild, moderate, and severe. The mild stage of AD usually exists for two to four years. The moderate stage of AD can last from two to 10 years. And, the severe stage of AD typically usually lasts for one to three years. In this final stage, physical and cognitive skills are severely affected; therefore, patients need extensive support with daily living and communication.

5Overall, more than 90% of AD cases belong to sporadic category which is suggested to be caused by complex genetic and environmental factors. Several risk factors are involved in the progression of AD. Aging is the greatest risk factor for the prevalence of AD. Another risk factor is family history of the disease. There are three genes identified for familial AD, including Amyloid Beta Precursor Protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2), but only one gene, Apolipoprotein E allele ε4 (APOEε4), is associated with the sporadic forms of AD. Other genetic factors, such as mutations in Triggering Receptor Expressed On Myeloid Cells 2 (TREM2), are also linked with high risk of late-onset AD. Sex is another risk factor for AD; females experience significant decreases in sex hormones starting at menopause, which increases the risk of AD.

6Histologically, AD is characterized by amyloid plaques, neurofibrillary tangles (NFTs), neuronal loss, and gliosis. Aβ is generated from the cleavage of APP by β-secretase (BACE1) and γ-secretase enzymes, Aβ monomers aggregate into oligomer forms of Aβ first and ultimately to amyloid plaques in the brain. Current theories suggest that Aβ peptides accumulate for more than a decade prior to the appearance of clinical symptoms in AD. NFTs, a crucial AD pathology, are insoluble twisted fibers, or the so-called tangles that are found inside neurons. The tangles consist mostly of a protein called tau, which is a component of microtubule organization. One of the functions of microtubules is to maintain an internal transport network for the trafficking of vesicles and other cargo inside the cells. In AD, tau protein is hyperphosphorylated, which leads to compromised microtubules, and hence, disruption of several cellular processes, such as proliferation, differentiation, protein trafficking, and cellular morphology (Figure 1). Although the accumulation of NFTs is correlated with the neuronal loss and cognitive decline, it is not certain if NFTs are the actual cause of neurodegeneration in AD.

3.1. Autophagy

7Autophagy (meaning “self-eating” in Greek) is one of the main pathways for the removal of damaged proteins and organelles. It works by carrying the protein aggregates and damaged organelles into lysosomes. However, the function of autophagy in neurons is more than just simple housekeeping tasks and involves several neuronal specific functions such as axonal guidance, synaptic transmission, proper neuronal connectivity, and neural stem cell development. In fact, the impairment of autophagy is suggested to be a major contributing factor to the brain dysfunction in neurodegeneration.

8Autophagy is categorized into three major forms: microautophagy, chaperone-mediated autophagy (CMA), and macroautophagy. These different forms of autophagy are discriminated based on the way that the targeted cargo is transported to lysosomes for degradation. Macroautophagy (hereafter autophagy) is the major form of autophagy in the cells. Autophagy is also induced by starvation. In this way, autophagy is important for cells by providing them with essential nutrients.

9The formation of autophagosome involves several steps, including the induction of autophagy, nucleation and the formation of autophagy membranes (i.e., phagophore), and expansion of the membrane to form a double membrane vesicle (i.e., autophagosome). It has been shown that in yeast, this process is highly regulated by a set of “Autophagy Related Genes” (ATGs). ATGs are evolutionary conserved genes and their paralogues exist in higher species including mammals. Within the cells, the products of these genes interact and form multi-molecular complexes, which are responsible for the regulation of different steps of autophagy. These complexes in mammalian cells include the ULK1/2-ATG13-FIP200 complex, the PtdIn3K complex, and the ubiquitin-like conjugation complex Atg12-Atg5-ATG16L (Figure 2).

10The ULK1/2-ATG13-FIP200 complex plays a pivotal role in the induction of autophagy. This complex consists of unc-51-like autophagy-activating kinase 1 (ULK1, the mammalian homologue of yeast Atg1), ATG13, ATG101a, and FIP200 (AKA RB1CC1) (Figure 2A). Under physiologic conditions, this complex is inhibited by mTORC1 complex. During starvation, mTORC1 complex is inhibited and ULK1/2-ATG13-FIP200 complex initiates the autophagy process within cells. In addition, starvation and energy depletion activates 5′-adenosine monophosphate activated protein kinase (AMPK), which results in the phosphorylation of ULK1 and nucleation of ULK1/2-ATG13-FIP200 complex (Figure 2A). It is believed that mitochondria-associated endoplasmic reticulum membranes (MAMs) are the origin of autophagy membranes.

11The ULK1/2-ATG13-FIP200 complex activates Beclin1 complex (consisting of ATG14L-Beclin1-hVps34-p150). Upon activation, both complexes translocate to the site of nucleation of autophagy membrane, phagophore (Figure 2B). As a result, membrane lipid phosphatidylinositol is phosphorylated, generating phosphatidylinositol 3-phosphate (PtdIns(3)P) on the surface of the phagophores. PtdIns(3)P is recognized by proteins such as WIPI2, resulting in the recruitment of ATG16L to phagophores (Figure 2E). This results in activation of two ubiquitin-like conjugation complex involved in autophagy. First, ATG12 is conjugated to ATG5 by the function of ATG7 and ATG10. The ATG12/ATG5 conjugate then makes a complex with ATG16L (Figure 2C). Then, the ATG12/ATG5/ATG16L complex binds to and activates ATG3, resulting in the conjugation of a second complex; ATG8/LC3 and phosphatidylethanolamine (PE) on the surface of autophagosomes (Figure 2D). It seems that these two ubiquitin-like conjugation complexes are interconnected, and together mediate the formation of autophagosomes and navigate their fusion with lysosomes.

3.2. Dysregulation of Autophagy in AD

12There is solid evidence that autophagy flux is impaired in AD. In cells, the formation of different types of autophagy vacuoles (AVs) follows a distinct order. First, autophagosomes are formed by the extension of phagophore membranes. Then, amphisomes are formed by fusion of autophagosomes with endosomes. Finally, autolysosomes are made through fusion of amphisomes or autophagosomes with lysosomes. One of the striking ultrastructural changes in AD is the accumulation of all forms of AVs inside affected neurons. Indeed, the magnitude of AVs accumulation in AD is so high that it resembles some primary lysosome storage disorders (LSDs) (Figure 3). Multilamellar bodies (MLBs) are membrane-bound cellular organelles, which accumulate inside the cells under pathologic conditions, such as LSDs, and represent impaired cholesterol and lipid metabolism. Accumulation of MLBs is also reported within dystrophic neurites in AD. It is noteworthy to mention that some LSDs are accompanied with hallmarks of AD (e.g., NFTs and upregulated amyloidogenic process); however, this association happens during the very early stages of life.

13Impaired autophagy was also confirmed in laboratory models of AD. Mutations in PS1 genes are among the genetic causes of AD. Using fibroblasts derived from AD patients, it was shown that mutations of the PS1 gene results in disruption of lysosomal acidification/proteolysis. In one interesting study, it was observed that depletion of PS1 in neurons derived from induced pluripotent stem cells (iPSCs) impaired the formation of autophagosomes. The authors also found that the expression of several autophagy-related genes was diminished in these cells mediated through ERK/CREB signaling pathway in a γ-secretase-independent manner. Autophagy is also impaired in other mouse models of AD; mice overexpressing mutant APP show disrupted autophagy, probably due to the toxic effect of the β-secretase-cleaved carboxyl-terminal fragment (βCTF) of APP on lysosomes.

14It has been shown that mutations in ATG genes can recapitulate neurodegenerative phenotypes in mice. Conditional knock outs of Atg5 and Atg7 genes in mouse models resulted in accumulation of polyubiquitinated proteins as cytoplasmic inclusion bodies and eventually death of neurons. On the other hand, the enhancement of autophagy in mouse models of neurodegenerative disorders (for example through inhibition of mTORC1) reduces the number of cytoplasmic inclusion bodies and improves the phenotype in these animals. In addition, the enhancement of autophagy alleviated memory loss in several animal models of AD paralleled by lower levels of Aβ42, Aβ40 and hyperphosphorylated Tau in brain tissue. Lysosomal biogenesis is regulated by transcription factor EB (TFEB). Overexpression of TFEB in mouse models of AD also reduced the number of protein deposits and alleviated behavioral abnormalities.

15Impaired autophagy is also connected to production and accumulation of Aβ in AD. Yu et al. reported that isolated AVs from brain tissues of AD mice are enriched in APP, Aβ peptides, and gamma secretase complexes. Another study showed that inhibition of autophagy flux in healthy neurons results in accumulation of APP enriched AVs in perikarya and neurites Beclin1, the mammalian orthologue of yeast Atg6, plays a pivotal role in autophagy through facilitating lipid membrane extension, cargo recruitment, and autophagosome maturation. It has been shown that the levels of Beclin1 is decreased in the affected brain areas of patients with AD during early stages of the disease. Additionally, overexpression of Beclin1 in a mouse model of AD diminished both intracellular and extracellular amyloid aggregation.

4.1. Mitophagy

16Mitochondria are the main source of energy in neurons and their proper function is crucial for synaptic transmission, calcium homeostasis, redox signaling, synaptic plasticity, and neuronal survival.. As the power engines of the cells, all the components of mitochondria are prone to severe oxidative damage. Damaged mitochondria contribute to cell toxicity and death through generation of excessive amounts of reactive oxygen species (ROS). Therefore, the presence of a powerful mitochondrial quality control (MQC) system is pivotal for cells to screen and neutralize such harmful events quickly. In cells, the MQC system includes several mechanisms including those involving mitochondrial fission and fusion, mitochondrial unfolded protein responses (mUPR), and mitophagy Mitochondria possess very dynamic biogenesis processes that respond to major damage by generating new and healthy mitochondria that fuse to the existing mitochondria, or by segregation of the unrecoverable mitochondria, which are degraded through mitophagy.

17Mitophagy, the selective form of autophagy for mitochondria, is a crucial process for neuronal health and survival (summarized in Figure 4). Impaired mitophagy has been implicated in the pathogenesis of several neurodegenerative disorders, such as AD and Parkinson’s disease (PD). The molecular mechanisms underlying selective autophagy of mitochondria has not been fully deciphered. Several studies have suggested that sustained depolarization of the mitochondrial inner membrane stabilizes the PTEN-induced kinase 1 (PINK1) on the outer mitochondrial membrane (OMM) (Figure 4). Consequently, phosphorylation of mitofusin2 (Mfn2) and ubiquitin molecules by PINK1 results in recruitment of Parkin, an E3 ubiquitin ligase, to the OMM. Finally, several proteins on damaged mitochondria are ubiquitinated by Parkin and become recognizable for autophagy receptor proteins, such as optineurin (OPTN), NDP52, p62, and NBR. Recent studies discovered more mitophagy receptors, including Autophagy and Beclin1 Regulator 1 (AMBRA1), BCL2 Interacting Protein 3 Like (BNIP3L/Nix), and FUN14 Domain Containing 1 (FUNDC1). AMBRA1 can induce mitophagy via binding to LC3 in both Parkin-dependent and -independent manners. Nix (AKA BNIP3L) was first recognized as a mitophagy receptor in erythroid cells; however, it has been shown that Nix can induce mitophagy in a variety of other cell types including neurons. FUNDC1 is a mitophagy receptor protein and induces mitophagy under hypoxic conditions (Figure 4). After targeting the damaged mitochondria, mitophagy receptors covalently bind to the nascent autophagosomes’ proteins, LC3 and GABARAP, and form protein bridges between the phagophore membrane and the OMM. This leads to the elongation (mediated by LC3) and closure (mediated by GABARAP) of the phagophore membrane and results in complete engulfment of mitochondrion (Figure 2G). Fusion of lysosomes with autophagosomes is the last stage of mitophagy, which happens through the binding of PLEKHM1 and HOPS (on the phagosome) with Rab7 (on the lysosome) (Figure 2H). Finally, the engulfed mitochondrion breaks down inside the lysosome by the function of hydrolase enzymes (Figure 2I).

18BCL2 like 13 (BCL2L13, also known as BCL-Rambo) is a BCL2 like gene. It contains all four BH domains and a single transmembrane domain. BCL2L13 was first considered as a pro-apoptotic gene.. However, Murakawa et al. showed that this gene is indeed a mammalian orthologue to yeast ATG32 and induces mitophagy independent of the Parkin pathway. The authors showed that BCL2L13 binds to LC3-II leading towards engulfment of mitochondria within an autophagosome. BCL2L13 is constitutively expressed in the human fetus and promotes embryonic development. Additionally, it has been shown that BCL2L13 has a role in the regulation of energy metabolism and fat homeostasis.

4.2. Dysfunction of Mitochondria in AD

19Accumulating evidence have revealed that mitochondrial dysfunctions appear very early in the course of AD (even before the appearance of Aβ plaques and NFTs). These include downregulation of the enzymes involved in the tricarboxylic acid cycle (TCA) cycle, reduced oxidative phosphorylation and increased ROS production. PET scan studies on AD patients have shown that glucose uptake is decreased in several brain regions, which is known as the “hypometabolism state of AD brain,” which is probably due to large-scale mitochondrial dysfunction. The level of PGC-1-alpha, the master regulator of mitochondrial biogenesis, is reduced in brain samples of AD patients, suggesting that mitochondrial biogenesis is also impaired in AD. In addition, several studies on brain samples from AD patients confirmed accumulation of impaired mitochondria in neurons within the affected brain regions. Indeed, it seems that the clearance of damaged mitochondria (e.g., through mitophagy) is severely compromised in AD.

20A body of evidence supports the role of Aβ/tau pathology in mitochondrial dysfunction in AD. Overexpression of APP in cultured neurons results in extensive abnormal function and defective biogenesis of mitochondria. Aβ and p-tau interact directly with several mitochondrial components (e.g., VDAC1 and complex IV) and interfere with their functions. Several studies on samples from AD patients and mouse models also revealed that the mitochondrial permeability transition pore (mPTP) is dysregulated in AD, resulting in various types of mitochondrial dysfunction, such as decreased mitochondrial transmembrane potential, decreased mitochondrial respiration rates, increased ROS production, and mitochondrial swelling in AD brain.

21It was shown that in a cell line model of AD, Aβ oligomers (AβOs) induce mitochondrial fragmentation accompanied by reduced mitofusin1 and 2 (Mfn1/2) levels. It has also been reported that excessive generation of ROS by AβOs activates the Cyclin-dependent kinase 5 (Cdk5) pathway, which in turn results in decreased expression of Mfn1/2. Additional work revealed that AβOs mediate activation of dynamin-related protein 1 (Drp1), the fundamental component of mitochondrial fission machinery, resulting in enhanced fragmented mitochondria and subsequent cell death in AD.

22Increased cytoplasmic calcium is detrimental for neurons and might result in neuronal death. Endoplasmic reticulum (ER) and mitochondria are the main reservoirs of intracellular calcium and play a crucial role in calcium homeostasis inside cells. It has been shown that Aβos disrupt the intracellular calcium balance, and hence, impair the normal function of mitochondria. Previous reports also demonstrated that Aβ enhances glutamatergic neurotransmission via N-methyl-D-aspartate receptors (NMDARs) and increases tau phosphorylation, which might initiate neuronal cell death via mitochondrial pathways (Figure 3).

23Tau pathology also contributes to the mitochondrial dysfunction in AD. Several groups reported that p-tau results in downregulation of Optic Dominant Atrophy 1 (Opa1) and Drp1, and upregulation of Mfn1/2. Additionally, p-tau blocks mitophagy by inhibiting the recruitment of Parkin to damaged mitochondria (Figure 4). Hyperphosphorylation of tau also induces alterations in the binding ability of tau to microtubules and leads to formation of paired helical filament (PHF) and disruption of axonal transport of mitochondria in AD.

24Does mitochondria dysfunction contribute to the pathogenesis of AD or is it merely a consequence of other pathologic events, such as Aβ or p-tau aggregation? Mutations in mitochondrial fusion genes have been shown to result in mitochondrial fragmentation and AD pathologies. In addition, inhibition of mitochondria complex I (via administration of rotenone) induced tau pathology in rat brain. Additionally, it has been shown that oxidative stress increases the activity of the γ-secretase complex, where this phenomenon is mediated through post-translational modifications of one of its components, nicastrin by 4-hydroxynonenal. Similarly, excessive ROS contributes to p-tau aggregation through phospholipid peroxidation. On the other hand, selective depletion of mitochondrial cytochrome c oxidase (COX) in neurons alleviated amyloid pathology in a mouse model of AD. Thus, it seems that while Aβ and p-tau aggregation aggravate mitochondrial dysfunction, mitochondrial dysfunction also enhances Tau phosphorylation and Aβ aggregation. Indeed, there might be a vicious cycle between mitochondria dysfunction and classic AD pathologies.

4.3. Dysfunction of Mitophagy in AD

25It is believed that mitophagy is severely compromised in AD (Figure 3). Impaired mitophagy results in the accumulation of damaged mitochondria within neurons and contributes to the neurodegenerative process (Figure 3). Recent advancements in ultrasensitive next generation sequencing (NGS) disclosed the unusual accumulation of mitochondria DNA (mtDNA) mutations within the brain of patients with AD, which is believed to be due to accumulation of damaged mitochondria in neurons. Additionally, base excision repair (BER) and DNA double-strand break repair (DSBR) are two major DNA repair pathways in neurons, which are downregulated in AD. Interestingly, Ataxia Telangiectasia Mutated (ATM), a DNA repair gene downregulated in AD, plays an important role in autophagy and mitophagy. However, the precise relationship between defective DNA repair and mitophagy/autophagy impairment is not clear yet and needs further studies to determine the exact nature of causality.

26Sirtuin1 (SIRT1) and Sirtuin3 (SIRT3) are two genes with neuroprotective characteristics. Reductions in SIRT1 and SIRT3 activities have been reported in neurodegenerative conditions, including AD. It seems that SIRT1 executes its neuroprotective function by induction of autophagy/mitophagy via deacetylation of autophagy proteins, such as ATG5, ATG7, and ATG8/LC3. SIRT1 also stabilizes PINK1 and upregulates mitophagy proteins including LC3 and Nix/BNIP3L. Therefore, disruptions of SIRT1 function result in suppression of mitophagy and subsequent accumulation of damaged mitochondria in neurons. SIRT3 is an activator of FOXO3; it has been shown that the function of FOXO3 is essential for autophagic flux in neurons.

27Neural NAD+ deficiency has also been suggested as another potential reason for mitophagy impairment in AD. The proper homeostasis of intracellular ATP and NAD+ levels is crucial for neuronal function and survival. Optimum levels of NAD+ affect neuronal health by maintaining a fine balance between mitophagy and mitochondrial biogenesis. It has been shown that decreased level of NAD+ triggers the aggregation of misfolded proteins that compromises mitophagy and ultimately results in neuronal death.

5.1. Neuroinflammation in AD

28Neuroinflammation has been implicated to play a substantial role in AD. It has been shown that activation of microglia precedes Aβ and tau pathologies within the brain of AD patients and animal models. Additionally, increased levels of inflammatory mediators (e.g., IL-1β) have been consistently reported in AD brain. Inflammasomes are multi-protein complexes that play pivotal roles in inflammatory pathways inside the cells. They become activated upon exposure of cells to pathogen-associated molecular patterns (PAMP) or danger-associated molecular patterns (DAMP) and promotes the cleavage of Caspase-1 and the release of inflammatory cytokines such as IL-1β and IL-18. In the brain, NLRP3 and NLRP1 (two sensor components of inflammasome complexes) are expressed in neurons and microglia. It has been reported that both NLRP3 and NLRP1 inflammasomes are over-activated in AD. Halle et al. reported that Aβ is a potent activator of inflammasomes in microglia The authors showed that upon phagocytosis by microglia, Aβ induces lysosomal damage and leakage of Cathepsin B into cytosol resulting in activation of inflammasomes.

29Thus far, the efficacy of several anti-inflammatory therapeutics has been tested for AD treatment (https://www.alzforum.org/therapeutics/timeline/inflammation, accessed on 10 March 2021). We believe that the success of the anti-inflammatory approach highly depends on further discovery of molecular events, which specifically mediate over-activation of microglia in AD brain. For this mean, after providing a brief background about microglia, we will discuss how microglia is over-activated in AD by providing current evidence about the role of its surface receptors. Then, we will review current knowledge about the role of several mediators of inflammation, which are known to target and activate microglia in AD.

5.2. Microglia

30As a part of the innate immune system, microglia play an important role in maintaining brain homeostasis in the central nervous system (CNS). These “macrophage-like” cells account for virtually 10% of the cell population in a healthy adult brain. Microglia react rapidly to the changes in their microenvironments and play important roles in CNS homeostasis under normal and pathologic conditions, including tissue damage and infection.

31Initial microscopic examinations of the brain implied that under normal conditions, microglia remain in their spatial coordinates for a long time and show no obvious activity. Thus, the term “resting microglia” was coined to describe them at this stage. However, it has now been established that the “resting microglia,” indeed, monitor their surrounding environments very actively through constant remodeling of their processes. Additionally, microglia provide support for the neurons in some parts of the brain by secretion of neurotrophic factors such as insulin-like growth factors (IGF). As a matter of fact, frequent functional and structural interactions between neurons and microglia directly influence several fundamental events in the CNS, such as neural plasticity and brain development.

5.3.1. Complement Receptors

32It has been shown that the expression levels of complement receptors in microglia are increased in AD. Upregulation of complement receptors in AD seems to contribute to Aβ plaque formation, Aβ phagocytosis, and Aβ-mediated inflammation. Interestingly, activation of microglial complement receptors in AD is associated with an upregulation of the nuclear factor kappa B (NF-κB) signaling pathway. This finding suggests that NF-κB-dependent microglia activation might be a crucial contributor to AD. Crehan et al. reported that blockage of complement receptors in AD inhibits microglial activation and leads to neuronal protection. Furthermore, silencing the complement receptors rescued tau pathology and reversed tau-mediated inflammation in AD brain. Additionally, depletion of complement receptors prevents AD-associated dysfunctional phagocytosis, which suggests a role for the complement system in AD etiology.

5.3.2. Fc Receptors

33It has been shown that microglial FcRs interact with Aβ peptides, suggesting a role for FcRs in AD pathogenesis. Microglial FcR-mediated phagocytosis triggers the expression of cytokine genes, leading to inflammatory cascades. FcRs activation in primary human microglia stimulates certain immunoglobulins and induces macrophage inflammatory protein (MIP)-1α through activation of the NF-κB pathway. In accordance with this, depletion of microglial FcRs suppresses tau pathology and neuroinflammation in AD. Additionally, administration of antibodies against FcRs could lower tau absorption rates by microglia. Several lines of evidence revealed that microglial FcRs are also involved in Aβ phagocytosis. Antibodies against Aβ peptide triggered AD microglia to clear Aβ plaques through FcR-mediated phagocytosis. This finding suggests that the anti-Aβ antibody increases microglial-mediated clearance of Aβ in an Fc-dependent phagocytosis manner. However, some groups reported that Fc binding is not required for clearance of Aβ by microglia.

5.3.3. Scavenger Receptors

34A recent analysis of brain samples from APP23 transgenic mice showed high levels of Scavenger Receptor A-1 (SCARA-1) in microglia surrounding Aβ plaques. Additionally, microglia derived from SCARA-1 knockout mice displayed a significant reduction in Aβ phagocytosis by microglia. These findings suggest that SCARA-1 is involved in Aβ clearance by microglia.

35Class B of scavenger receptors, SCARB-2 (AKA CD36), is expressed by microglia in AD brains. Binding of CD36 to Aβ mediates activation of microglia to produce ROS, proinflammatory cytokines, and chemokines associated with AD. Upon activation, CD36 forms heterodimers with TLR-4 and TLR-6 on microglia, resulting in an increase of production of ROS and IL-β. Khoury et al. reported that microglia derived from CD36 knockout mice produce fewer amounts of pro-inflammatory cytokines such as TNFα and IL-1β upon exposure to Aβ. Additional evidence showed that CD36 increases the expression of NF-κB subunits significantly in cells expressing TLR4-TLR6. These findings suggest that CD36 plays a critical role in Aβ-induced ROS production in AD microglia. In accordance with these findings, injection of Aβ into CD36 knock-out mouse brains induced less accumulation of microglia, suggesting a significant role of CD36 in mediating inflammation in response to Aβ stimulation.

5.3.4. Receptor for Advanced Glycation Endproducts (RAGE)

36Several lines of evidence have reported that inflammatory processes found in AD are linked to microglia activation by Aβ interaction with RAGE. RAGE is a member of the immunoglobulin (Ig) superfamily of cell surface molecules with high homology to the neural cell adhesion molecules (N-CAM) and MUC18. Thus far, several ligands have been identified for RAGE with important roles in diabetes, inflammation, tumors, and neurodegeneration. RAGE has a large (344 amino acid long) extracellular domain and a single transmembrane domain. Using atomic force microscopy, Chaney et al. showed that soluble RAGE binds to soluble Aβ and inhibits aggregation of Aβ peptides. On the other hand, interaction of Aβ with membrane bound RAGE elaborates inflammatory response.

37The expression of RAGE is increased in AD brain. In AD brain, Aβ interacts with RAGE, which activates NF-κB signaling pathways in microglia and enhances the production of inflammatory mediators and ROS. Deane et al. showed that blocking RAGE in an AD mouse model reduced RAGE-Aβ interactions and decreased oxidative damage. On the other hand, microglial overexpression of RAGE in a transgenic-AD mouse model increased the production of proinflammatory mediators such as IL-1β, IL-6, and TNF-α after Aβ treatment.

38Interestingly, it has been reported that binding of Aβ to RAGE mediates Aβ endocytosis. Park et al. reported that knockdown of RAGE prevented accumulation of intracellular Aβ and the subsequent cellular toxicities. Interestingly, inhibition of p38 MAPK prevented internalization of Aβ peptides, suggesting that p38 acts downstream of RAGE for endocytosis of Aβ peptides.

39Aβ also binds to RAGE on the surface of neurons and induces the expression and release of macrophage-colony stimulating factor (M-CSF) by neurons. M-CSF is a strong activator of microglia represented by upregulation of scavenger receptors and ApoE, and production of excessive ROS in these cells.

5.3.5. Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)

40TREM2 is a microglial receptor highly expressed in AD brains. Depletion of TREM2 impairs Aβ phagocytosis by microglia, implying that TREM2-Aβ interaction may be crucial for clearance of amyloid plaques in AD brain. Another study showed that a deficiency of TREM2 decreases Aβ-associated microglia in an AD mouse model. However, a recent study showed that overexpression of TREM2 did not alter the amount of amyloid plaque in AD brain. Earlier studies suggested that loss of TREM2 function mitigates neuroinflammation, which protects brain atrophy in the context of tauopathy. In one study, TREM2 gene knockout in AD mice resulted in reduced microglial activity and tau pathology, while in another study TREM2 deletion resulted in the elevated tau phosphorylation and aggregation. These seemingly contradictory results on Aβ and tau load in TREM2−/− AD mouse models might be due to the type or age of the mouse models being used and mandate more investigations to address the role of TREM2 in Aβ pathology.

5.3.6. CD33

41CD33 is a membrane receptor expressed on myeloid cells. CD33 expression is increased in microglial cells in AD brain. CD33 seems to interfere with Aβ clearance by microglia. Indeed, high CD33 levels in AD brains were associated with lower microglial clearance of Aβ, while a deletion of CD33 in AD mice attenuated Aβ pathology. Interestingly, microglial TREM2 and CD33 display reverse effects on microglial activity as well as Aβ pathology in AD mice. It has been shown that CD33 knockout increases microglial activation and production of inflammatory mediators in AD mice, while TREM2 knockout has opposite effects. It seems that TREM2 acts as a downstream target of CD33; however, the exact nature of crosstalk between CD33 and TREM2 in the context of AD needs more investigation.

5.3.7. Toll-like Receptors (TLRs)

42A high level of TLRs has been detected in brain samples of AD mouse models. Moreover, mutations in TLR genes displayed reduced microglial activity and increased Aβ levels in the brain of AD mouse models. Microglia derived from TLR knock-out mice showed a significant reduction in the production of ROS upon exposure to Aβ, which links TLR to the oxidative response induced by Aβ. There is additional evidence suggesting TLRs trigger various signaling pathways in microglia that lead to the production of proinflammatory molecules and clearance of Aβ. Microglia derived from TLR knockdown mice displayed reduced expression of TNF-α, IL-1β, and IL-6. TLR knockdown mice also showed decreased expression levels of proinflammatory molecules after injection of Aβ into their brain cortex. These findings suggest that inhibition of TLRs in AD brain could delay AD progression by decreasing neuroinflammation and improving Aβ clearance. The expression of TLRs has been revealed to be associated with an increase in the level of tau in AD brains. These findings designate that TLR signaling is associated with tau pathology. Interestingly, a major signaling target of the TLRs is NF-κB, which induces inflammatory cytokines such as IL-1β, IL-6, and IL-8. Several lines of evidence report that TLR-mediated NF-κB activation is conserved throughout the evolution of phylogenetically different species.

5.4.1. Apolipoprotein E (APOE4)

43APOE4 is mainly expressed by microglia in the brain. APOE4 increases the risk of AD through deficient Aβ and tau clearance by impairing microglial phagocytosis. APOE4 has been also shown to impact Aβ clearance by the blood–brain barrier (BBB) and decreases Aβ plaque load. Additional evidence in a mouse model of tauopathy demonstrated that APOE affects tau pathology, independent of Aβ pathology. In AD brain, microglial APOE provides a protective Aβ- and tau-induced inflammatory response such as TNFα and IL6. The expression and activity of APOE4 is elevated after brain injury. Several studies show that APOE protects BBB integrity through NF-κB signaling in AD. Another study found that upregulation of APOE by Aβ in human astroglia is regulated by the NF-κB signaling pathway. Moreover, all APOE isoforms bind to TREM2 in AD. APOE-TREM2 binding results in the transcriptional shift of AD microglia from a homeostatic phenotype to a neurodegenerative phenotype.

5.4.2. Chemokines

44Both in vitro and in vivo studies reported that microglial chemokine ligand1 (CX3CL1; fractalkine) also plays a critical role in AD pathology. CX3CL1 is likely to alter the microglial state to a more neuroprotective one by acting on the microglial chemokine receptor 1 (CX3CR1) in microglia. Impairment of CX3CL1-CX3CR1 results in microglial dysfunction. The expression of CX3CL1 is elevated in AD brain. CX3CL1-CX3CR1 plays a critical neuroprotective role in brain by reducing inflammatory mediators (e.g., TNF-α, IL-1β, IL-6), neurotoxicity, and microglial activity. Silencing CX3CR1 in AD mouse models displayed increased expression of inflammatory markers and enhanced AD pathology. Additional evidence shows that deletion of microglial CX3CR1 elevated the activity of the NF-κB signaling pathway, which results in elevated levels of chemokines such as IL-1β.

45The CXCL12/CXCR4 pathway is among the most important neuroprotective pathways in CNS. CXCR4 is expressed by all cell types in the brain and plays several roles during the development of neurons. Its natural ligand, CXCL12, is upregulated by pro-inflammatory mediators such as IL-1, TNF-α and LPS. CXCL12 also has an important role in the maintenance and recovery of neurons. For example, CXCL12 signaling promotes neuronal repair after brain damage by recruiting neural stem cells to the site of injury. It has been reported that the activity of the CXCR4/CXCL12 pathway is severely diminished in AD. Additionally, inhibition of this pathway in mice resulted in cognitive deficits in this animal. On the other hand, increased levels of CXCL12 were shown to be protective against the neurotoxic effects of Aβ in mouse brain.

5.4.3. High Mobility Group Box 1 (HMGB1)

46Alarmins are endogenous equivalents of PAMPS, which are released following non-programmed cell death and recruit and activate receptor expressing cells of the innate immune system. High mobility group box 1 (HMGB1) and S100 proteins are endogenous molecules that meet all the criteria to be classified as alarmins and play important roles in neuroinflammation.

47HMGB1 resides primarily in the nucleus and has a role in chromatin architecture. However, HMGB1 is released to the extracellular spaces under conditions such as infection, injury, inflammation, and non-programmed cell death. HMGB1 can be also secreted actively by activated myeloid cells. It has been shown that inflammasomes are the key regulators of active release of HMGB1. HMGB1 signaling is indeed at the cross section of sterile and pathogen induced inflammation. On its target cells, HMGB1 can bind to TLR2, TLR4, and RAGE and activate inflammatory responses. Recently, Volchuk et al. reported that HMGB1 is only released under conditions that cause cell lysis (e.g., pyroptosis).

48The levels of HMGB1 are increased in AD, which is believed to contribute further to neuroinflammation in this disease. It is also reported that HMGB1 binds to Aβ within extracellular space and reduces its clearance by microglia.

49It has been suggested that HMGB1 can serve as a viable therapeutic target in several conditions related to neuroinflammation. In an interesting experiment, Fujita et al. showed that injection of an antibody against HMGB1 inhibits neurite degeneration and recovers cognitive impairment in a mouse model of AD.

5.4.4. S100 Proteins

50S100 proteins (aka calgranulins) are a family of 25 calcium-binding proteins, which are released by activated myeloid cells to induce inflammation. S100 proteins have several intracellular and extracellular functions. Inside the cells, S100 proteins are involved in biologic functions, such as cell proliferation, cytoskeletal kinetics, and calcium homeostasis. S100 proteins are also secreted into the extracellular space, and indeed, act as DAMP molecules and stimulate immune cells by binding to receptors like RAGE and activate proinflammatory pathways such as NF-κB signaling. S100 proteins play important roles in the brain homeostasis and several of them are reported to be involved in AD pathogenesis (including S100B, S100A1, S100A6, S100A7, S100A8, S100A9, and S100A12). Among them, S100 β is specifically expressed in the brain and is strongly associated with Aβ pathology in AD.

51S100B is mainly produced by astrocytes in the brain. Its expression is regulated by cytokines such as TNF-α. At low expression levels (i.e., nanomolar concentrations), S100B acts as a neurotrophic and neuroprotective cytokine and protects neurons against neurotoxic cytokines and compounds such as TNF-α and glutamate. On the other hand, higher concentrations of S100B (e.g., the ones reported in pathologic conditions such as AD and HIV infection) are detrimental to neurons through acute stimulation of RAGE. Indeed, serum concentration of S100B increases drastically in AD patients and correlates with the severity of the disease.

52It has been reported that high concentrations of S100B induce neuronal apoptosis through over-activation of ERK1/2, resulting in the excessive production of ROS and NOS in neurons. At high concentrations, S100B also acts as a DAMP and activates microglia through binding to RAGE. This interaction mediates the activation of several parallel proinflammatory pathways in microglia including Ras/Rac1/NF-κB and Cdc42/Rac1/JNK/AP-1 and consequent expression and release of IL-1β, TNF-α, and COX-2.

53S100A8 and S100A9 are expressed by neurons and microglia in CNS and the levels of both peptides are significantly increased in AD. S100A8/A9 heteromer is a potent proinflammatory cytokine and activates microglia through binding to TLRs. Treatment of neuroblastoma cells with recombinant S100A8 increased Aβ42 production by these cells. Additionally, exposure of microglia derived from AD patients to aggregated Aβ increased the expression of S100A8 in these cells. It has been reported that S100A9 is able to mimic the behavior of Aβ peptides in the formation of polymeric structures that resemble amyloid architectures such as oligomers and fibrils. Nasal administration of these forms of S100A9 resulted in impaired memory and learning in mice. Co-aggregation of S100A9 with Aβ is also reported in AD. Post-mortem examinations have revealed the accumulation of S100A9 within amyloid plaques of sporadic and familial AD brains. Interestingly, depletion of S100A9 in Tg2576 mice alleviated the cognitive deficits and Aβ aggregation in these mice.

6. Autophagy and Neuroinflammation in AD

54Autophagy and inflammation are two biologic processes that are upregulated in cells in response to several stressful events. Interestingly, the two pathways interact at several points and modulate each other in a bidirectional manner. In general, it is shown that inflammation induces autophagy inside the cells. Th1 cytokines (including IFN-γ, TNF-α, IL-1, IL-2, IL-6, and TGF-β) are proinflammatory cytokines, while Th2 cytokines (e.g., IL-4, IL-10 and IL-13) suppress inflammation. It has been reported that Th1 cytokines activate autophagy, while Th2 cytokines inhibit autophagy in the cells. On the other hand, autophagy itself is a regulator of inflammation inside the cells. It has been reported that autophagy decreases the secretion of proinflammatory cytokines, including IL-1β, IL-6, and TNF-α through the degradation of several components of inflammatory machinery in the cells. In this way, cells seem to use autophagy as negative feedback to modulate the cytotoxic effects of inflammation. Therefore, impaired autophagy is implicated in sustained inflammation in tissues and might contribute to pathogenesis of chronic inflammatory conditions.

6.1. Role of Impaired Autophagy in Neuroinflammation

55During neurodegenerative conditions, an excessive amount of misfolded protein aggregates leads to microglial activation and neuroinflammation. It has been shown that induction of autophagy in general is effective in the mitigation of this inflammatory condition. Specifically, induction of autophagy in microglia ameliorates neuroinflammation due to degradation of misfolded proteins, damaged mitochondria (i.e., mitophagy), and activated inflammasomes.

56It has been proposed that prolonged exposure to Aβ impairs microglial autophagy in AD. This hypothesis was suggested by evidence from AD experimental models and patients that show dysregulation of autophagy in microglia. It has been reported that the formation of autolysosomes is diminished within microglia in AD due to impaired fusion of autophagosomes with lysosomes. Furthermore, the integrity of the lysosomal membrane is compromised due to the Aβ exposure. In an innovative experiment, Stoka et al. utilized Cathepsin D tracing and showed that the structure of the microglial lysosome is preserved after a short (2-h) exposure to Aβ. However, long exposure (24 h) to Aβ resulted in lysosome permeabilization, indicated by extra lysosomal Cathepsin D. In addition, neuroinflammation is another factor contributing to the impaired autophagy in the cells exposed to Aβ peptides. It was shown that the inflammasome-forming NLRP3 and the pro-inflammatory cytokine TNFα are involved in impaired autophagy in microglia isolated from AD animal models.

57Several studies showed that enhancing autophagy in neurons is protective against accumulation of misfolded and damaged proteins in AD brain. Specifically, mounting evidence highlight a pivotal link between autophagy and microglial function in the nervous system (for detailed explanation please see Figure 5). Microglia are the main player of the Aβ-induced immune response in AD and contribute to neurodegeneration and synaptic dysfunction in this disease. Microglia are also involved in phagocytosis of a wide range of cellular debris, such as apoptotic bodies, axonal fragments, and Aβ and p-tau deposits. It has been shown that there is a close crosstalk between autophagy and phagocytosis in microglia. Phagocytosis shares many molecular pathways with autophagy. It is an evolutionarily conserved mechanism in which recognition, engulfment, and lysosomal degradation of extracellular materials occurs by immune cells such as microglia and macrophages.

58Mediators of autophagy orchestrate phagocytosis in microglia in various ways (for details, review Figure 5). For example, LC3 is associated with phagocytosis, a process known as LC3-associated phagocytosis (LAP). During this cellular event, LC3 recruitment to the single-membrane phagosomes is mediated by the activity of ATG5 and ATG7 (Figure 5). Thereafter, Beclin1 and LC3 proteins translocate to the phagosome’s membrane, allowing the fusion of phagosome with lysosome (Figure 5). This process induces rapid acidification and degradation of the ingested organisms. The cooperation of autophagy mediators with phagocytosis enhances the efficiency of microglial phagocytosis in the elimination of extracellular pathogens. In a very recent study, Heckmann et al. showed that enhancement of LC3-associated endocytosis (LANDO), a distinct but similar pathway to LAP, facilitates the clearance of Aβ and alleviates neurodegeneration in murine models of AD. They showed that LANDO is essential for recycling of Aβ receptors (e.g., TREM2) in microglia, and requires the function of Rubicon, Beclin1, ATG5, and ATG7 genes (Figure 5). The authors also reported that this process protects against Aβ-mediated neuronal loss and memory impairment in a murine model of AD.

59Accumulation of apoptotic bodies has been reported in AD. Surprisingly, inhibition of autophagy in Drosophila brains via inhibition of ATG1 and mTORC1 complex, does not lead to neurodegeneration. Thus, it seems that the removal of apoptotic cell bodies by microglia occurs through the activation of LAP and phagocytosis. It can be conferred that LAP may prevent neurodegeneration, even in the absence of autophagy flux.

60Microglial Beclin1 acts as a regulator of Aβ removal and phagocytosis in AD. Interestingly, the level of Beclin1 is significantly reduced in microglia isolated from human AD brains. In microglia, Beclin1 is involved in the regulation of phagocytosis through regulating the expression of microglia surface receptors TREM2 and CD36. Additionally, it has been shown that Beclin1-driven autophagy modulates the response of Nre3 inflammasomes. As mentioned before, neuroinflammation is an early hallmark in the course of AD. In a recent study, Houtman et al. reported that depletion of Beclin1 may affect cytokine production by microglia. Based on their study, there was a significant increase in the production of proinflammatory cytokines IL-1β and IL-18 by the activated microglia lacking Beclin1. This is remarkable evidence of how impaired autophagy may contribute to increased neuroinflammation in AD.

61Autophagy can reduce neuroinflammation through degradation of inflammasome and subsequent suppression of IL-1β secretion. IL-1β is a key player in the activation of microglia. Harris et al. reported that autophagy also induces the lysosomal degradation of pro-IL-1β peptide. Accordingly, inhibition of autophagy resulted in increased secretion of IL-1β in an NLRP3- and TRIF-dependent manner. Finally, Bussi et al. reported that induction of autophagy leads to a significant reduction in production of IL-1β, IL-6, TNF-α and NO in BV2 microglial cells. Autophagy induction also inhibited LPS-induced p38 and ERK1/2 phosphorylation in a p38 MAPK and NO-dependent manner.

6.2. Role of Neuroinflammation in Impairment of Autophagy

62The notion of impaired autophagy in AD is against the fact that inflammation in general results in activation of autophagy in cells. Among the increased proinflammatory factors in AD, HMGB1, S100A8/A9, complement receptor, Fc receptors, scavenger receptors, RAGE, TLRs, and CXCR4 have all been reported to induce autophagy in the cells. Thus, it seems that other factors contribute to the regulation of autophagy in AD.

63Thus far, several studies have been conducted trying to find how autophagy is regulated in AD. TLR4 is suggested as one of the main mediators of neuronal damage in AD. Qin et al. reported that stimulation of TLR4 by LPS in tau-transgenic mice resulted in enhancement of neuronal autophagy, which was associated with a reduction of cerebral p-Tau proteins and improved cognitive function. TLR2 has been reported as the receptor for Aβ peptides mediating inflammatory response in microglia upon exposure to Aβ. Arroyo et al. reported that activation of microglial TLR2 using peptidoglycan (PGN) enhances autophagy and results in autophagy-dependent cell death of these cells. Furthermore, François et al. indicated a positive correlation between inflammatory mediators (IL-1β, TNF-α and IL-6) and the expression level of the main autophagy regulators (mTOR and Beclin-1) in the brain of mice with mutations of App and Psen1 genes. All of these studies interpreted that AD and neuroinflammation feed neuro-protective autophagic mechanisms, but their findings just added to the level of controversy. One explanation could be the fact that all of these studies used humanized mouse models of genetic forms of AD hence might not represent the majority sporadic AD cases in human. Interestingly, it is shown that TREM2 and APOE4 (two genes associated with sporadic AD) negatively regulate autophagy in cells. Additionally, it has been reported that NLRP3 negatively affects autophagy flux through downregulation of PINK1 leading to accumulation of misfolded proteins in AD.

7.1. Role of Impaired Mitophagy in Inflammation

64It is believed that mitochondria were incorporated about 1.5 billion years ago through the endosymbiosis of an α-protobacterium in eukaryotic cells. Mitochondria still contain several molecular features from their bacterial ancestors. Moreover, if not removed through the function of mitophagy, these molecules may release from damaged mitochondria and serve as pathogen-associated molecular patterns (PAMPs) and activate pattern recognition receptors (PRRs).

65Similar to bacteria, mitochondria have circular DNA harboring unmethylated CpG elements. It has been shown that mtDNA interacts with Cyclic GMP-AMP Synthase (cGAS) and NLRP3 (two important proinflammatory molecules inside the cells) and with Toll-like receptor 9 (TLR-9) when released in to the intracellular space. In accordance with this, injection of mtDNA (but not genomic DNA) resulted in tissue inflammation and injury in several animal models.

66Under conditions with excessive generation of ROS, several mitochondrial components, including mtDNA, are oxidized. Excessive ROS also results in the opening of the mitochondrial transition pores (MPTP) mediating the leaking of oxidized mtDNA into the cytoplasm. Within the cells, oxidized mtDNA is a potent proinflammatory signal and results in production of interleukin-1 beta (IL-1β) and IL-18. Depletion of mtDNA in macrophages (e.g., by cyclosporine) suppressed the production of IL-1β and IL-18 by these cells. It has been shown that the inhibition of autophagy in macrophages increases the accumulation of cytosolic mtDNA in response to lipopolysaccharide (LPS) and ATP. On the other hand, enhancing mitophagy diminished the levels of cytoplasmic mtDNA and inhibited the subsequent activation of the inflammasome. Other mitochondrial derived molecules, which can act as DAMPs, are Adenosine Triphosphate (ATP), Cardiolipin, and Formyl-Peptides.

67Adding to the level of complexity, mitochondria themselves also contribute to the regulation of danger responses inside the cells and acts as a platform for the transduction of inflammatory signals. Intracellular viral RNAs are detected by two cytosolic proteins Retinoic Acid- Inducible Gene I (RIG-I)-Like Receptors (RLRs) and melanoma differentiation-associated protein 5 (MDA5). Mitochondrial Antiviral Signaling Protein (MAVS) is located in the outer membrane and acts as an adaptor for activated RLRs and relays signals that lead into the activation of key inflammatory genes, such as NF-κB, IFN-I, and IFN-III in the cells. It has been shown that the inhibition of mitophagy enhances MAVS-mediated inflammatory responses through increased production of mtROS and consequent lipid peroxidation of mitochondrial outer membranes. Since IFN-I, itself, is a potent enhancer of mtROS, the RLRs/MAVS pathway is thought to be involved in conditions with chronic sustained inflammation. Strikingly, it has been shown recently that IFN-1 is a key driving factor for neuroinflammation and synaptic loss in AD.

68Likewise, mitochondria also contribute to the regulation of inflammatory responses against exogenous DNA (e.g., from DNA viruses). Cytosolic DNA molecules are detected by the Cyclic GMP-AMP Synthase (cGAS) enzyme. Upon binding to DNA, cGAS increases the levels of cyclic GMP-AMP, which acts as a secondary messenger for Stimulator of Interferon Genes (STING). Under normal conditions, STING is located on mitochondria-associated ER membranes (MAMs) in association with MAVS. After activation, STING translocates to Golgi and perinuclear endosomes and mediates the activation of IRF-3 and NF-κB in the cells. It has been suggested that association with mitochondria might negatively regulate the activity of STING through mediating its ubiquitination and degradation.

7.2. Mitophagy and Microglia in AD

69As mentioned before, accumulation of damaged mitochondria contributes to inflammation within the cells through release of ROS and oxidized biomaterials. Thus, it is believed that the enhancement of mitophagy may reverse neuroinflammation in AD by the removal of damaged mitochondria. Indeed, it has been reported that mitophagy is impaired severely in microglia isolated from AD brains. In a recent study, Fang et al. showed that enhancement of mitophagy inhibits Aβ and p-tau pathology, and reverses cognitive deficits in an animal model of AD. Accordingly, it was reported that mitochonic acid 5 (MA-5, an inducer of mitophagy) protects mouse microglia against TNFα-induced apoptosis through activation of MAPK–ERK–Yap pathways. This protective effect was mediated by the function of BCL2/adenovirus E1B 19-kDa protein-interacting protein 3 (Bnip3). Upon induction of mitophagy, Bnip3 translocates to the outer membrane of mitochondria and acts as a mitophagy receptor, possibly interacting with LC3 to facilitate fusion of damaged mitochondria with lysosomes.

8. Concluding Remarks

70After more than a century of the first description of AD, the real cause(s) of this disorder is (are) still unknown. The amyloid hypothesis has been the dominant theory for AD pathogenesis for more than three decades, but all the clinical trials targeting Aβ have so far failed or show only modest efficacy. Currently, the role of neuroinflammation in AD is under extensive investigation and it has been shown that Aβ is a strong proinflammatory mediator in the brain. As the main brain immune cells, microglia play an important role in neuroinflammation. One of the most striking findings in AD is impaired autophagy. Recent studies on microglia isolated from AD brain confirmed that autophagy is also severely impaired in these cells. Since the crosstalk between autophagy and inflammation is important to prevent noxious effects of inflammation in cells, it is quite plausible to consider that lack of an effective autophagy process in microglia contributes to an aberrant sustained inflammatory state as observed in AD. Interestingly, it seems that the induction of autophagy and mitophagy might show some beneficial effects in AD.

71Although extensive impairments of autophagy are reported in AD, the exact nature of these pathologies is still unclear. For example, activation of inflammatory pathways in general results in upregulation of autophagy flux in cells as a downstream event. However, reduction in autophagy flux reported does not parallel the neuroinflammatory state reported in the AD brain. Thus, further comprehensive studies are required to find exactly which components of autophagy and mitophagy pathways are affected in AD, as well as how the impairments of autophagy flux affect the inflammatory processes in the AD brain. Specially, it is very important to decipher the crosstalk of autophagy and inflammation within microglia in an attempt to discover more diagnostic biomarkers and therapeutic options in AD.

References 383

1.
History and progress of hypotheses and clinical trials for Alzheimer’s disease · 2019
Corrected
2.
Kidd M. Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature. 1963;197:192-193.
Not in our library10.1038/197192b0
3.
Terry R.D. The fine structure of neurofibrillary tangles in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 1963;22:629-642.
Not in our library10.1097/00005072-196310000-00005
4.
Glabe C.C. Amyloid accumulation and pathogensis of Alzheimer’s disease: Significance of monomeric, oligomeric and fibrillar Abeta. Sub-Cell. Biochem. 2005;38:167-177.
Not in our library10.1007/0-387-23226-5_8
5.
Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353-356.
Not in our library10.1126/science.1072994
6.
Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research · 2019
No notice
7.
Hickman S., Izzy S., Sen P., Morsett L., El Khoury J. Microglia in neurodegeneration. Nat. Neurosci. 2018;21:1359-1369.
Not in our library10.1038/s41593-018-0242-x
8.
Li J.W., Zong Y., Cao X.P., Tan L., Tan L. Microglial priming in Alzheimer’s disease. Ann. Transl. Med. 2018;6:176.
Not in our library10.21037/atm.2018.04.22
9.
Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell. 2017;169:1276-1290.e17.
Not in our library10.1016/j.cell.2017.05.018
10.
Ghavami S., Shojaei S., Yeganeh B., Ande S.R., Jangamreddy J.R., Mehrpour M., Christoffersson J., Chaabane W., Moghadam A.R., Kashani H.H., et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 2014;112:24-49.
Not in our library10.1016/j.pneurobio.2013.10.004
11.
Wells C.E. Dementia: Definition and description. Contemp. Neurol. Ser. 1977;15:1-14.
Not in our library
12.
2015 WAsR. The Global Impact of Dementia: An analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International 2015.
Not in our library
13.
Prince M., Wimo A., Guerchet M., Ali G.C., Wu Y.T., Prina M. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. 2015.
Not in our library
14.
World Health Organization (WHO) Dementia Fact Sheet 2019.
Not in our library
15.
Dementia.
Not in our library
16.
Wimo A., Jonsson L., Bond J., Prince M., Winblad B. Alzheimer Disease I. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2013;9:1-11.e3.
Not in our library10.1016/j.jalz.2012.11.006
17.
Sam Vandongen S.C. WA Reports. 2011.
Not in our library
18.
Adlimoghaddam A., Roy B., Albensi B.C. Future Trends and the Economic Burden of Dementia in Manitoba: Comparison with the Rest of Canada and the World. Neuroepidemiology. 2018;51:71-81.
Not in our library10.1159/000490414
19.
Chappell N.L., Hollander M.J. An evidence-based policy prescription for an aging population. Healthcarepapers. 2011;11:8-18.
Not in our library10.12927/hcpap.2011.22246
20.
Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
Not in our library10.2165/00002512-199915050-00004
21.
Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(Suppl. 5):S10-S15.
Not in our library
22.
Aarsland D., Rongve A., Nore S.P., Skogseth R., Skulstad S., Ehrt U., Hoprekstad D., Ballard C. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement. Geriatr. Cogn. Disord. 2008;26:445-452.
Not in our library10.1159/000165917
23.
Disease Burden and Mortality Estimates.
Not in our library
24.
Cummings J.L. Treatment of Alzheimer’s disease: Current and future therapeutic approaches. Rev. Neurol. Dis. 2004;1:60-69.
Not in our library
25.
Cummings J.L. Alzheimer’s disease. New Engl. J. Med. 2004;351:56-67.
Not in our library10.1056/nejmra040223
26.
Adlimoghaddam A., Neuendorff M., Roy B., Albensi B.C. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci. Ther. 2018;24:876-888.
Not in our library10.1111/cns.13035
27.
Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18:351-357.
Not in our library10.1016/s0197-4580(97)00056-0
28.
Small G.W., Rabins P.V., Barry P.P., Buckholtz N.S., DeKosky S.T., Ferris S.H., Finkel S.I., Gwyther L.P., Khachaturian Z.S., Lebowitz B.D., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA. 1997;278:1363-1371.
Not in our library10.1001/jama.1997.03550160083043
29.
Meek P.D., McKeithan K., Schumock G.T. Economic considerations in Alzheimer’s disease. Pharmacotherapy. 1998;18((2 Pt 2)):68-73.
Not in our library10.1002/j.1875-9114.1998.tb03880.x
30.
Lopez O.L., Becker J.T., Sweet R.A., Klunk W., Kaufer D.I., Saxton J., Habeych M., DeKosky S.T. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J. Neuropsychiatry Clin. Neurosci. 2003;15:346-353.
Not in our library10.1176/jnp.15.3.346
31.
van der Flier W.M., Scheltens P. Epidemiology and risk factors of dementia. J. Neurol. Neurosurg. Psychiatry. 2005;76(Suppl. 5):v2-v7.
Not in our library10.1136/jnnp.2005.082867
32.
Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011;7:137-152.
Not in our library10.1038/nrneurol.2011.2
33.
Group CSoHaAW. The Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada. Neurology. 1994;44:2073-2080.
Not in our library10.1212/wnl.44.11.2073
34.
Lindsay J.H.R., Rockwood K. The Canadian Study of Health and Aging: Risk factors for vascular dementia. Stroke. 1997;28:526-530.
Not in our library10.1161/01.str.28.3.526
35.
Hebert R., Lindsay J., Verreault R., Rockwood K., Hill G., Dubois M.F. Vascular dementia: Incidence and risk factors in the Canadian study of health and aging. Stroke. 2000;31:1487-1493.
Not in our library10.1161/01.str.31.7.1487
36.
Bekris L.M., Yu C.-E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010;23:213-227.
Not in our library10.1177/0891988710383571
37.
Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112-2117.
Not in our library10.1016/s0140-6736(05)67889-0
38.
Donix M., Ercoli L.M., Siddarth P., Brown J.A., Martin-Harris L., Burggren A.C., Miller K.J., Small G.W., Bookheimer S.Y. Influence of Alzheimer disease family history and genetic risk on cognitive performance in healthy middle-aged and older people. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry. 2012;20:565-573.
Not in our library10.1097/jgp.0b013e3182107e6a
39.
Pizzonia J.H., Ransom B.R., Pappas C.A. Characterization of Na+/H+ exchange activity in cultured rat hippocampal astrocytes. J. Neurosci. Res. 1996;44:191-198.
Not in our library10.1002/(sici)1097-4547(19960415)44:2<191::aid-jnr12>3.0.co;2-9
40.
Tiraboschi P., Hansen L.A., Masliah E., Alford M., Thal L.J., Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977-1983.
Not in our library10.1212/01.wnl.0000128091.92139.0f
41.
Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1993;90:9649-9653.
Not in our library10.1073/pnas.90.20.9649
42.
Zheng H., Cheng B., Li Y., Li X., Chen X., Zhang Y.W. TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism. Front. Aging Neurosci. 2018;10:395.
Not in our library10.3389/fnagi.2018.00395
43.
Podcasy J.L., Epperson C.N. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin. Neurosci. 2016;18:437-446.
Not in our library10.31887/dcns.2016.18.4/cepperson
44.
Riggs B.L., Khosla S., Melton L.J. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1998;13:763-773.
Not in our library10.1359/jbmr.1998.13.5.763
45.
Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189.
Not in our library10.1101/cshperspect.a006189
46.
Hyman B.T. The neuropathological diagnosis of Alzheimer’s disease: Clinical-pathological studies. Neurobiol. Aging. 1997;18:S27-S32.
Not in our library10.1016/s0197-4580(97)00066-3
47.
Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010;12:1-12.
Not in our library10.1007/s12017-009-8104-z
48.
Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119-128.
Not in our library10.1016/s1474-4422(09)70299-6
49.
Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects · 2019
No notice
50.
Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 2010;7:656-664.
Not in our library10.2174/156720510793611592
51.
Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
Not in our library10.1007/bf00308809
52.
Morris J.C. Early-stage and preclinical Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2005;19:163-165.
Not in our library10.1097/01.wad.0000184005.22611.cc
53.
Krishnan S., Shrestha Y., Jayatunga D.P.W., Rea S., Martins R., Bharadwaj P. Activate or Inhibit? Implications of Autophagy Modulation as a Therapeutic Strategy for Alzheimer’s Disease. Int. J. Mol. Sci. 2020;21:6739.
Not in our library10.3390/ijms21186739
54.
Shojaei S., Suresh M., Klionsky D.J., Labouta H.I., Ghavami S. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway. Virulence. 2020;11:805-810.
Not in our library10.1080/21505594.2020.1780088
55.
Shojaei S., Koleini N., Samiei E., Aghaei M., Cole L.K., Alizadeh J., Islam M.I., Vosoughi A.R., Albokashy M., Butterfield Y., et al. Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. FEBS J. 2020;287:1005-1034.
Not in our library10.1111/febs.15069
56.
Alizadeh J., Shojaei S., Sepanjnia A., Hashemi M., Eftekharpour E., Ghavami S. Simultaneous Detection of Autophagy and Epithelial to Mesenchymal Transition in the Non-small Cell Lung Cancer Cells. Methods Mol. Biol. 2019;1854:87-103.
Not in our library10.1007/7651_2017_84
57.
Hwang J.Y., Yan J., Zukin R.S. Autophagy and synaptic plasticity: Epigenetic regulation. Curr. Opin. Neurobiol. 2019;59:207-212.
Not in our library10.1016/j.conb.2019.09.010
58.
Autophagy regulates Notch degradation and modulates stem cell development and neurogenesis · 2016
No notice
59.
Zeng Q., Siu W., Li L., Jin Y., Liang S., Cao M., Ma M., Wu Z. Autophagy in Alzheimer’s disease and promising modulatory effects of herbal medicine. Exp. Gerontol. 2019;119:100-110.
Not in our library10.1016/j.exger.2019.01.027
60.
Uddin M.S., Mamun A.A., Labu Z.K., Hidalgo-Lanussa O., Barreto G.E., Ashraf G.M. Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis. J. Cell Physiol. 2019;234:8094-8112.
Not in our library10.1002/jcp.27588
61.
Ghavami S., Gupta S., Ambrose E., Hnatowich M., Freed D.H., Dixon I.M. Autophagy and heart disease: Implications for cardiac ischemia-reperfusion damage. Curr. Mol. Med. 2014;14:616-629.
Not in our library10.2174/1566524014666140603101520
62.
Samiei E., Seyfoori A., Toyota B., Ghavami S., Akbari M. Investigating Programmed Cell Death and Tumor Invasion in a Three-Dimensional (3D) Microfluidic Model of Glioblastoma. Int. J. Mol Sci. 2020;21:3162.
Not in our library10.3390/ijms21093162
63.
Mehdizadeh M., Ashtari N., Jiao X., Rahimi Balaei M., Marzban A., Qiyami-Hour F., Kong J., Ghavami S., Marzban H. Alteration of the Dopamine Receptors’ Expression in the Cerebellum of the Lysosomal Acid Phosphatase 2 Mutant (Naked-Ataxia (NAX)) Mouse. Int. J. Mol. Sci. 2020;21:2914.
Not in our library10.3390/ijms21082914
64.
Dastghaib S., Shojaei S., Mostafavi-Pour Z., Sharma P., Patterson J.B., Samali A., Mokarram P., Ghavami S. Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells. Cells. 2020;9:2339.
Not in our library10.3390/cells9112339
65.
Zaffagnini G., Martens S. Mechanisms of Selective Autophagy. J. Mol Biol. 2016;428((9 Pt A)):1714-1724.
Not in our library10.1016/j.jmb.2016.02.004
66.
Sainani S.R., Pansare P.A., Rode K., Bhalchim V., Doke R., Desai S. Emendation of autophagic dysfuction in neurological disorders: A potential therapeutic target. Int. J. Neurosci. 2020;1-17.
Not in our library10.1080/00207454.2020.1822356
67.
da Silva Rosa S.C., Martens M.D., Field J.T., Nguyen L., Kereliuk S.M., Hai Y., Chapman D., Diehl-Jones W., Aliani M., West A.R., et al. BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA/PKA phosphorylation. Autophagy. 2020;1-16.
Not in our library10.1080/15548627.2020.1821548
68.
McAlinden K.D., Kota A., Haghi M., Ghavami S., Sharma P. Pharmacologic Inhibition of Vacuolar H(+)ATPase Attenuates Features of Severe Asthma in Mice. Am. J. Respir. Cell Mol. Biol. 2020;62:117-120.
Not in our library10.1165/rcmb.2019-0141le
69.
Yang Z., Klionsky D.J. Mammalian autophagy: Core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 2010;22:124-131.
Not in our library10.1016/j.ceb.2009.11.014
70.
Tyler J.K., Johnson J.E. The role of autophagy in the regulation of yeast life span. Ann. N. Y. Acad. Sci. 2018;1418:31-43.
Not in our library10.1111/nyas.13549
71.
Suzuki K., Kubota Y., Sekito T., Ohsumi Y. Hierarchy of Atg proteins in pre-autophagosomal structure organization. Genes Cells. 2007;12:209-218.
Not in our library10.1111/j.1365-2443.2007.01050.x
72.
Iranpour M., Moghadam A.R., Yazdi M., Ande S.R., Alizadeh J., Wiechec E., Lindsay R., Drebot M., Coombs K.M., Ghavami S. Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis. Expert Rev. Mol. Med. 2016;18:e1.
Not in our library10.1017/erm.2015.19
73.
Shi X., Yokom A.L., Wang C., Young L.N., Youle R.J., Hurley J.H. ULK complex organization in autophagy by a C-shaped FIP200 N-terminal domain dimer. J. Cell Biol. 2020;219.
Not in our library10.1083/jcb.201911047
74.
Russell R.C., Tian Y., Yuan H., Park H.W., Chang Y.Y., Kim J., Kim H., Neufeld T.P., Dillin A., Guan K.L. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat. Cell Biol. 2013;15:741-750.
Not in our library10.1038/ncb2757
75.
Harada K., Kotani T., Kirisako H., Sakoh-Nakatogawa M., Oikawa Y., Kimura Y., Hirano H., Yamamoto H., Ohsumi Y., Nakatogawa H. Two distinct mechanisms target the autophagy-related E3 complex to the pre-autophagosomal structure. Elife. 2019;8:e43088.
Not in our library10.7554/elife.43088
76.
Papinski D., Kraft C. Regulation of autophagy by signaling through the Atg1/ULK1 complex. J. Mol. Biol. 2016;428:1725-1741.
Not in our library10.1016/j.jmb.2016.03.030
77.
Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., Iemura S., Natsume T., Takehana K., Yamada N., et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell. 2009;20:1981-1991.
Not in our library10.1091/mbc.e08-12-1248
78.
Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011;13:132-141.
Not in our library10.1038/ncb2152
79.
Mitochondria-Associated ER Membranes – The Origin Site of Autophagy · 2020
No notice
80.
Yeganeh B., Jager R., Gorman A.M., Samali A., Ghavami S., Hayat M.A. Induction of Autophagy: Role of Endoplasmic Reticulum Stress and Unfolded Protein Response. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. 5. 2015;91-101.
Not in our library
81.
The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections · 2019
No notice
82.
Otomo C., Metlagel Z., Takaesu G., Otomo T. Structure of the human ATG12~ ATG5 conjugate required for LC3 lipidation in autophagy. Nat. Struct. Mol. Biol. 2013;20:59.
Not in our library10.1038/nsmb.2431
83.
Rai S., Arasteh M., Jefferson M., Pearson T., Wang Y., Zhang W., Bicsak B., Divekar D., Powell P.P., Naumann R., et al. The ATG5-binding and coiled coil domains of ATG16L1 maintain autophagy and tissue homeostasis in mice independently of the WD domain required for LC3-associated phagocytosis. Autophagy. 2019;15:599.
Not in our library10.1080/15548627.2018.1534507
84.
Fang E.F., Hou Y., Palikaras K., Adriaanse B.A., Kerr J.S., Yang B., Lautrup S., Hasan-Olive M.M., Caponio D., Dan X., et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat. Neurosci. 2019;22:401-412.
Not in our library10.1038/s41593-018-0332-9
85.
Emami A., Shojaei S., da Silva Rosa S.C., Aghaei M., Samiei E., Vosoughi A.R., Kalantari F., Kawalec P., Thliveris J., Sharma P., et al. Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition. Eur. J. Pharmacol. 2019;862:172616.
Not in our library10.1016/j.ejphar.2019.172616
86.
Eskelinen E.L., Saftig P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta. 2009;1793:664-673.
Not in our library10.1016/j.bbamcr.2008.07.014
87.
Lorzadeh S., Kohan L., Ghavami S., Azarpira N. Autophagy and the Wnt Signaling Pathway: A Focus on Wnt/beta-catenin signaling. Biochim. Biophys. Acta Mol. Cell. Res. 2020;118926.
Not in our library10.1016/j.bbamcr.2020.118926
88.
Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005;64:113-122.
Not in our library10.1093/jnen/64.2.113
89.
Terry R.D., Gonatas N.K., Weiss M. The ultrastructure of the cerebral cortex in Alzheimer’s disease. Trans. Am. Neurol. Assoc. 1964;89:12.
Not in our library
90.
Nixon R.A., Yang D.S., Lee J.H. Neurodegenerative lysosomal disorders: A continuum from development to late age. Autophagy. 2008;4:590-599.
Not in our library10.4161/auto.6259
91.
Lajoie P., Guay G., Dennis J.W., Nabi I.R. The lipid composition of autophagic vacuoles regulates expression of multilamellar bodies. J. Cell Sci. 2005;118((Pt 9)):1991-2003.
Not in our library10.1242/jcs.02324
92.
Nixon R.A., Yang D.S. Autophagy failure in Alzheimer’s disease--locating the primary defect. Neurobiol. Dis. 2011;43:38-45.
Not in our library10.1016/j.nbd.2011.01.021
93.
Chong C.M., Ke M., Tan Y., Huang Z., Zhang K., Ai N., Ge W., Qin D., Lu J.H., Su H. Presenilin 1 deficiency suppresses autophagy in human neural stem cells through reducing γ-secretase-independent ERK/CREB signaling. Cell Death Dis. 2018;9:879.
Not in our library10.1038/s41419-018-0945-7
94.
Yang D.S., Stavrides P., Mohan P.S., Kaushik S., Kumar A., Ohno M., Schmidt S.D., Wesson D., Bandyopadhyay U., Jiang Y., et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011;134((Pt 1)):258-277.
Not in our library10.1093/brain/awq341
95.
Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880-884.
Not in our library10.1038/nature04723
96.
Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885-889.
Not in our library10.1038/nature04724
97.
Sarkar S., Perlstein E.O., Imarisio S., Pineau S., Cordenier A., Maglathlin R.L., Webster J.A., Lewis T.A., O’Kane C.J., Schreiber S.L., et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat. Chem. Biol. 2007;3:331-338.
Not in our library10.1038/nchembio883
98.
Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O’Kane C.J., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585-595.
Not in our library10.1038/ng1362
99.
Chauhan R., Chen K.F., Kent B.A., Crowther D.C. Central and peripheral circadian clocks and their role in Alzheimer’s disease. Dis. Model. Mech. 2017;10:1187-1199.
Not in our library10.1242/dmm.030627
100.
Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB · 2014
No notice
101.
Yu W.H., Kumar A., Peterhoff C., Shapiro Kulnane L., Uchiyama Y., Lamb B.T., Cuervo A.M., Nixon R.A. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: Implications for beta-amyloid peptide over-production and localization in Alzheimer’s disease. Int. J. Biochem. Cell Biol. 2004;36:2531-2540.
Not in our library10.1016/j.biocel.2004.05.010
102.
Boland B., Kumar A., Lee S., Platt F.M., Wegiel J., Yu W.H., Nixon R.A. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer’s disease. J. Neurosci. 2008;28:6926-6937.
Not in our library10.1523/jneurosci.0800-08.2008
103.
Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., Mohan P.S., Mercken M., Farmery M.R., Tjernberg L.O., et al. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol. 2005;171:87-98.
Not in our library10.1083/jcb.200505082
104.
Maejima Y., Isobe M., Sadoshima J. Regulation of autophagy by Beclin 1 in the heart. J. Mol. Cell Cardiol. 2016;95:19-25.
Not in our library10.1016/j.yjmcc.2015.10.032
105.
Pickford F., Masliah E., Britschgi M., Lucin K., Narasimhan R., Jaeger P.A., Small S., Spencer B., Rockenstein E., Levine B., et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Investig. 2008;118:2190-2199.
Not in our library10.1172/jci33585
106.
Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60:748-766.
Not in our library10.1016/j.neuron.2008.10.010
107.
Stockburger C., Eckert S., Eckert G.P., Friedland K., Müller W.E. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer’s Disease. J. Alzheimer’s Dis. 2018;64:S455-S467.
Not in our library10.3233/jad-179915
108.
Chu J., Lauretti E., Praticò D. Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3β kinase: Implications for Alzheimer’s disease. Mol. Psychiatry. 2017;22:1002-1008.
Not in our library10.1038/mp.2016.214
109.
Means J.C., Gerdes B.C., Kaja S., Sumien N., Payne A.J., Stark D.A., Borden P.K., Price J.L., Koulen P. Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary Tangles and Results in Cognitive Impairment During Normal Aging. Neurochem. Res. 2016;41:2278-2288.
Not in our library10.1007/s11064-016-1942-9
110.
Ułamek-Kozioł M., Kocki J., Bogucka-Kocka A., Januszewski S., Bogucki J., Czuczwar S.J., Pluta R. Autophagy, mitophagy and apoptotic gene changes in the hippocampal CA1 area in a rat ischemic model of Alzheimer’s disease. Pharm. Rep. 2017;69:1289-1294.
Not in our library10.1016/j.pharep.2017.07.015
111.
Green D.R., Van Houten B. SnapShot: Mitochondrial quality control. Cell. 2011;147:950.e1.
Not in our library10.1016/j.cell.2011.10.036
112.
Alterations in Mitochondrial Quality Control in Alzheimer’s Disease · 2016
No notice
113.
Mitochondrial Quality Control and Disease: Insights into Ischemia-Reperfusion Injury · 2017
No notice
114.
Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease · 2019
No notice
115.
Sekine S. PINK1 import regulation at a crossroad of mitochondrial fate: The molecular mechanisms of PINK1 import. J. Biochem. 2020;167:217-224.
Not in our library10.1093/jb/mvz069
116.
Wang Y., Liu N., Lu B. Mechanisms and roles of mitophagy in neurodegenerative diseases. CNS Neurosci. Ther. 2019;25:859-875.
Not in our library10.1111/cns.13140
117.
Lou G., Palikaras K., Lautrup S., Scheibye-Knudsen M., Tavernarakis N., Fang E.F. Mitophagy and Neuroprotection. Trends Mol. Med. 2020;26:8-20.
Not in our library10.1016/j.molmed.2019.07.002
118.
Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer’s Disease Pathogenesis · 2019
No notice
119.
Kerr J.S., Adriaanse B.A., Greig N.H., Mattson M.P., Cader M.Z., Bohr V.A., Fang E.F. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 2017;40:151-166.
Not in our library10.1016/j.tins.2017.01.002
120.
Heckmann B.L., Teubner B.J.W., Tummers B., Boada-Romero E., Harris L., Yang M., Guy C.S., Zakharenko S.S., Green D.R. LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer’s Disease. Cell. 2019;178:536-551.e14.
Not in our library10.1016/j.cell.2019.05.056
121.
Kataoka T., Holler N., Micheau O., Martinon F., Tinel A., Hofmann K., Tschopp J. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J. Biol. Chem. 2001;276:19548-19554.
Not in our library10.1074/jbc.m010520200
122.
Meng F., Sun N., Liu D., Jia J., Xiao J., Dai H. BCL2L13: Physiological and pathological meanings. Cell. Mol. Life Sci. 2020;1-10.
Not in our library10.1007/s00018-020-03702-9
123.
Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation · 2015
No notice
124.
Boumela I., Assou S., Aouacheria A., Haouzi D., Dechaud H., De Vos J., Handyside A., Hamamah S. Involvement of BCL2 family members in the regulation of human oocyte and early embryo survival and death: Gene expression and beyond. Reproduction. 2011;141:549-561.
Not in our library10.1530/rep-10-0504
125.
Fujiwara M., Tian L., Le P.T., DeMambro V.E., Becker K.A., Rosen C.J., Guntur A.R. The mitophagy receptor Bcl-2-like protein 13 stimulates adipogenesis by regulating mitochondrial oxidative phosphorylation and apoptosis in mice. J. Biol. Chem. 2019;294:12683-12694.
Not in our library10.1074/jbc.ra119.008630
126.
Cadonic C., Sabbir M.G., Albensi B.C. Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease. Mol. Neurobiol. 2016;53:6078-6090.
Not in our library10.1007/s12035-015-9515-5
127.
Adlimoghaddam A., Snow W.M., Stortz G., Perez C., Djordjevic J., Goertzen A.L., Ko J.H., Albensi B.C. Regional hypometabolism in the 3xTg mouse model of Alzheimer’s disease. Neurobiol. Dis. 2019;127:264-277.
Not in our library10.1016/j.nbd.2019.03.008
128.
Banerjee K., Munshi S., Frank D.E., Gibson G.E. Abnormal Glucose Metabolism in Alzheimer’s Disease: Relation to Autophagy/Mitophagy and Therapeutic Approaches. Neurochem. Res. 2015;40:2557-2569.
Not in our library10.1007/s11064-015-1631-0
129.
Albensi B.C. Dysfunction of mitochondria: Implications for Alzheimer’s disease. Int. Rev. Neurobiol. 2019;145:13-27.
Not in our library10.1016/bs.irn.2019.03.001
130.
Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol. 2011;10:187-198.
Not in our library10.1016/s1474-4422(10)70277-5
131.
Dong Y., Brewer G.J. Global Metabolic Shifts in Age and Alzheimer’s Disease Mouse Brains Pivot at NAD+/NADH Redox Sites. J. Alzheimer’s Dis. 2019;71:119-140.
Not in our library10.3233/jad-190408
132.
Marcus C., Mena E., Subramaniam R.M. Brain PET in the diagnosis of Alzheimer’s disease. Clin. Nucl. Med. 2014;39:e413-e426.
Not in our library10.1097/rlu.0000000000000547
133.
Róna-Vörös K., Weydt P. The role of PGC-1α in the pathogenesis of neurodegenerative disorders. Curr. Drug Targets. 2010;11:1262-1269.
Not in our library10.2174/1389450111007011262
134.
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update · 2019
No notice
135.
Xie C., Aman Y., Adriaanse B.A., Cader M.Z., Plun-Favreau H., Xiao J., Fang E.F. Culprit or Bystander: Defective Mitophagy in Alzheimer’s Disease. Front. Cell Dev. Biol. 2019;7:391.
Not in our library10.3389/fcell.2019.00391
136.
Reddy P.H., Yin X., Manczak M., Kumar S., Pradeepkiran J.A., Vijayan M., Reddy A.P. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Hum. Mol. Genet. 2018;27:2502-2516.
Not in our library10.1093/hmg/ddy154
137.
Manczak M., Reddy P.H. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum. Mol. Genet. 2012;21:5131-5146.
Not in our library10.1093/hmg/dds360
138.
Casley C.S., Canevari L., Land J.M., Clark J.B., Sharpe M.A. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 2002;80:91-100.
Not in our library10.1046/j.0022-3042.2001.00681.x
139.
Tillement L., Lecanu L., Yao W., Greeson J., Papadopoulos V. The spirostenol (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate blocks mitochondrial uptake of Abeta in neuronal cells and prevents Abeta-induced impairment of mitochondrial function. Steroids. 2006;71:725-735.
Not in our library10.1016/j.steroids.2006.05.003
140.
Mitochondrial Dysfunction: Different Routes to Alzheimer’s Disease Therapy · 2014
No notice
141.
Du H., Yan S.S. Mitochondrial permeability transition pore in Alzheimer’s disease: Cyclophilin D and amyloid beta. Biochim. Biophys. Acta. 2010;1802:198-204.
Not in our library10.1016/j.bbadis.2009.07.005
142.
Rao V.K., Carlson E.A., Yan S.S. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim. Biophys. Acta. 2014;1842:1267-1272.
Not in our library10.1016/j.bbadis.2013.09.003
143.
Park J., Choi H., Min J.S., Kim B., Lee S.R., Yun J.W., Choi M.S., Chang K.T., Lee D.S. Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells. J. Neurochem. 2015;132:687-702.
Not in our library10.1111/jnc.12984
144.
Kim D.I., Lee K.H., Gabr A.A., Choi G.E., Kim J.S., Ko S.H., Han H.J. Aβ-Induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis. Biochim. Biophys. Acta. 2016;1863:2820-2834.
Not in our library10.1016/j.bbamcr.2016.09.003
145.
Orrenius S., Gogvadze V., Zhivotovsky B. Calcium and mitochondria in the regulation of cell death. Biochem. Biophys. Res. Commun. 2015;460:72-81.
Not in our library10.1016/j.bbrc.2015.01.137
146.
PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death · 2009
No notice
147.
A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease · 2018
No notice
148.
Cheng J., Liao Y., Dong Y., Hu H., Yang N., Kong X., Li S., Li X., Guo J., Qin L. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy. 2020;1-13.
Not in our library10.1080/15548627.2020.1805860
149.
Zheng W.H., Bastianetto S., Mennicken F., Ma W., Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115:201-211.
Not in our library10.1016/s0306-4522(02)00404-9
150.
Garwood C.J., Pooler A.M., Atherton J., Hanger D.P., Noble W. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2011;2:e167.
Not in our library10.1038/cddis.2011.50
151.
Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration · 2018
No notice
152.
Manczak M., Reddy P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012;21:2538-2547.
Not in our library10.1093/hmg/dds072
153.
Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. USA. 2008;105:15997-16002.
Not in our library10.1073/pnas.0808084105
154.
Mandelkow E.M., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012;2:a006247.
Not in our library10.1101/cshperspect.a006247
155.
Kopeikina K.J., Carlson G.A., Pitstick R., Ludvigson A.E., Peters A., Luebke J.I., Koffie R.M., Frosch M.P., Hyman B.T., Spires-Jones T.L. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain. Am. J. Pathol. 2011;179:2071-2082.
Not in our library10.1016/j.ajpath.2011.07.004
156.
Andreadis A. Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta. 2005;1739:91-103.
Not in our library10.1016/j.bbadis.2004.08.010
157.
Leon-Espinosa G., Garcia E., Garcia-Escudero V., Hernandez F., Defelipe J., Avila J. Changes in tau phosphorylation in hibernating rodents. J. Neurosci. Res. 2013;91:954-962.
Not in our library10.1002/jnr.23220
158.
Amadoro G., Corsetti V., Stringaro A., Colone M., D’Aguanno S., Meli G., Ciotti M., Sancesario G., Cattaneo A., Bussani R., et al. A NH2 tau fragment targets neuronal mitochondria at AD synapses: Possible implications for neurodegeneration. J. Alzheimer’s Dis. 2010;21:445-470.
Not in our library10.3233/jad-2010-100120
159.
Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins · 2016
No notice
160.
DuBoff B., Gotz J., Feany M.B. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron. 2012;75:618-632.
Not in our library10.1016/j.neuron.2012.06.026
161.
Itoh K., Nakamura K., Iijima M., Sesaki H. Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 2013;23:64-71.
Not in our library10.1016/j.tcb.2012.10.006
162.
Cummins N., Tweedie A., Zuryn S., Bertran-Gonzalez J., Gotz J. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J. 2019;38:e99360.
Not in our library10.15252/embj.201899360
163.
Crespo-Biel N., Theunis C., Van Leuven F. Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer’s disease. Int. J. Alzheimer’s Dis. 2012;2012:251426.
Not in our library10.1155/2012/251426
164.
Structure and Pathology of Tau Protein in Alzheimer Disease · 2012
No notice
165.
Knott A.B., Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: A new mechanism of neurodegeneration. Ann. N. Y. Acad. Sci. 2008;1147:283-292.
Not in our library10.1196/annals.1427.030
166.
Höglinger G.U., Lannuzel A., Khondiker M.E., Michel P.P., Duyckaerts C., Féger J., Champy P., Prigent A., Medja F., Lombes A., et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J. Neurochem. 2005;95:930-939.
Not in our library10.1111/j.1471-4159.2005.03493.x
167.
Yoo S.M., Park J., Kim S.H., Jung Y.K. Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease. BMB Rep. 2020;53:35-46.
Not in our library10.5483/bmbrep.2020.53.1.274
168.
Guo L., Tian J., Du H. Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer’s Disease. J. Alzheimer’s Dis. 2017;57:1071-1086.
Not in our library10.3233/jad-160702
169.
The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease · 2018
No notice
170.
Agnihotri A., Aruoma O.I. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. J. Am. Coll. Nutr. 2020;39:16-27.
Not in our library10.1080/07315724.2019.1683379
171.
Fukui H., Diaz F., Garcia S., Moraes C.T. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2007;104:14163-14168.
Not in our library10.1073/pnas.0705738104
172.
Perez Ortiz J.M., Swerdlow R.H. Mitochondrial dysfunction in Alzheimer’s disease: Role in pathogenesis and novel therapeutic opportunities. Br. J. Pharmacol. 2019;176:3489-3507.
Not in our library10.1111/bph.14585
173.
Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases · 2020
No notice
174.
Castellazzi M., Patergnani S., Donadio M., Giorgi C., Bonora M., Bosi C., Brombo G., Pugliatti M., Seripa D., Zuliani G., et al. Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment. Sci. Rep. 2019;9:20009.
Not in our library10.1038/s41598-019-56614-5
175.
Sorrentino V., Romani M., Mouchiroud L., Beck J.S., Zhang H., D’Amico D., Moullan N., Potenza F., Schmid A.W., Rietsch S., et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature. 2017;552:187-193.
Not in our library10.1038/nature25143
176.
Coskun P.E., Beal M.F., Wallace D.C. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. USA. 2004;101:10726-10731.
Not in our library10.1073/pnas.0403649101
177.
Hoekstra J.G., Hipp M.J., Montine T.J., Kennedy S.R. Mitochondrial DNA mutations increase in early stage Alzheimer disease and are inconsistent with oxidative damage. Ann. Neurol. 2016;80:301-306.
Not in our library10.1002/ana.24709
178.
Malfatti M.C., Antoniali G., Codrich M., Burra S., Mangiapane G., Dalla E., Tell G. New perspectives in cancer biology from a study of canonical and non-canonical functions of base excision repair proteins with a focus on early steps. Mutagenesis. 2020;35:129-149.
Not in our library10.1093/mutage/gez051
179.
Gredilla R., Garm C., Stevnsner T. Nuclear and mitochondrial DNA repair in selected eukaryotic aging model systems. Oxidative Med. Cell. Longev. 2012;2012:282438.
Not in our library10.1155/2012/282438
180.
Chow H.M., Herrup K. Genomic integrity and the ageing brain. Nat. Rev. Neurosci. 2015;16:672-684.
Not in our library10.1038/nrn4020
181.
Hou Y., Song H., Croteau D.L., Akbari M., Bohr V.A. Genome instability in Alzheimer disease. Mech. Ageing Dev. 2017;161((Pt A)):83-94.
Not in our library10.1016/j.mad.2016.04.005
182.
Choy K.R., Watters D.J. Neurodegeneration in ataxia-telangiectasia: Multiple roles of ATM kinase in cellular homeostasis. Dev. Dyn. 2018;247:33-46.
Not in our library10.1002/dvdy.24522
183.
Amirifar P., Ranjouri M.R., Yazdani R., Abolhassani H., Aghamohammadi A. Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatr. Allergy Immunol. 2019;30:277-288.
Not in our library10.1111/pai.13020
184.
Li B., Liu J., Gu G., Han X., Zhang Q., Zhang W. Impact of neural stem cell-derived extracellular vesicles on mitochondrial dysfunction, sirtuin 1 level, and synaptic deficits in Alzheimer’s disease. J. Neurochem. 2020;154:502-518.
Not in our library10.1111/jnc.15001
185.
Mechanisms and disease implications of sirtuin-mediated autophagic regulation · 2019
Not checked
186.
Esteves A.R., Filipe F., Magalhães J.D., Silva D.F., Cardoso S.M. The Role of Beclin-1 Acetylation on Autophagic Flux in Alzheimer’s Disease. Mol. Neurobiol. 2019;56:5654-5670.
Not in our library10.1007/s12035-019-1483-8
187.
Meng H., Yan W.Y., Lei Y.H., Wan Z., Hou Y.Y., Sun L.K., Zhou J.P. SIRT3 Regulation of Mitochondrial Quality Control in Neurodegenerative Diseases. Front. Aging Neurosci. 2019;11:313.
Not in our library10.3389/fnagi.2019.00313
188.
Theurey P., Connolly N.M.C., Fortunati I., Basso E., Lauwen S., Ferrante C., Moreira Pinho C., Joselin A., Gioran A., Bano D., et al. Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer’s disease neurons. Aging Cell. 2019;18:e12924.
Not in our library10.1111/acel.12924
189.
Zhang M., Ying W. NAD(+) Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications. Antioxid. Redox Signal. 2019;30:890-905.
Not in our library10.1089/ars.2017.7445
190.
Hou Y., Lautrup S., Cordonnier S., Wang Y., Croteau D.L., Zavala E., Zhang Y., Moritoh K., O’Connell J.F., Baptiste B.A., et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl. Acad. Sci. USA. 2018;115:E1876-E1885.
Not in our library10.1073/pnas.1718819115
191.
Severini C., Barbato C., Di Certo M.G., Gabanella F., Petrella C., Di Stadio A., de Vincentiis M., Polimeni A., Ralli M., Greco A. Alzheimer’s disease: New concepts on the role of autoimmunity and of NLRP3 inflammasome in the pathogenesis of the disease. Curr. Neuropharmacol. 2020;21:18.
Not in our library10.2174/1570159x18666200621204546
192.
Zhang Y., Zhao Y., Zhang J., Yang G. Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer’s Disease. Neurochem. Res. 2020;45:2560-2572.
Not in our library10.1007/s11064-020-03121-z
193.
Tarkowski E., Andreasen N., Tarkowski A., Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2003;74:1200-1205.
Not in our library10.1136/jnnp.74.9.1200
194.
Neuroinflammation and Neuronal Loss Precede Aβ Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer’s Disease · 2013
No notice
195.
IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer’s disease: Systematic Review and Meta-Analysis · 2018
No notice
196.
Schroder K., Tschopp J. The inflammasomes. Cell. 2010;140:821-832.
Not in our library10.1016/j.cell.2010.01.040
197.
NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia but Not in Astrocytes · 2015
No notice
198.
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease · 2016
No notice
199.
Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008;9:857-865.
Not in our library10.1038/ni.1636
200.
Inflammation.
Not in our library
201.
Sarlus H., Heneka M.T. Microglia in Alzheimer’s disease. J. Clin. Investig. 2017;127:3240-3249.
Not in our library10.1172/jci90606
202.
Microglia: Agents of the CNS Pro-Inflammatory Response · 2020
No notice
203.
What Do Microglia Really Do in Healthy Adult Brain? · 2019
No notice
204.
Tremblay M.-È., Stevens B., Sierra A., Wake H., Bessis A., Nimmerjahn A. The role of microglia in the healthy brain. J. Neurosci. 2011;31:16064-16069.
Not in our library10.1523/jneurosci.4158-11.2011
205.
Tay T.L., Carrier M., Tremblay M.-È. Physiology of Microglia. Advances in Experimental Medicine and Biology. 2019;Volume 1175:129-148.
Not in our library10.1007/978-981-13-9913-8_6
206.
Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314-1318.
Not in our library10.1126/science.1110647
207.
Finsen B., Myhre C.L., Thygesen C., Villadsen B., Vollerup J., Ilkjær L., Jensen K.T., Grebing M., Zhao S., Khan A.M. Microglia express insulin-like growth factor-1 in the hippocampus of aged APPswe/PS1dE9 transgenic mice. Front. Cell Neurosci. 2019;13:308.
Not in our library10.3389/fncel.2019.00308
208.
The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and Cancer · 2017
No notice
209.
Loughlin A.J., Woodroofe M.N., Cuzner M.L. Regulation of Fc receptor and major histocompatibility complex antigen expression on isolated rat microglia by tumour necrosis factor, interleukin-1 and lipopolysaccharide: Effects on interferon-gamma induced activation. Immunology. 1992;75:170-175.
Not in our library
210.
Okun E., Mattson M.P., Arumugam T.V. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12:164-178.
Not in our library10.1007/s12017-009-8099-5
211.
Adlimoghaddam A., Odero G.G., Glazner G., Turner R.S., Albensi B.C. Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer’s disease. J. Aging Dis. 2020;12.
Not in our library10.14336/ad.2020.0910
212.
Adlimoghaddam A., Albensi B.C. The nuclear factor kappa B (NF-κB) signaling pathway is involved in ammonia-induced mitochondrial dysfunction. Mitochondrion. 2020;57:63-75.
Not in our library10.1016/j.mito.2020.12.008
213.
Blockage of CR1 prevents activation of rodent microglia · 2013
Not checked
214.
Litvinchuk A., Wan Y.W., Swartzlander D.B., Chen F., Cole A., Propson N.E., Wang Q., Zhang B., Liu Z., Zheng H. Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease. Neuron. 2018;100:1337-1353.e5.
Not in our library10.1016/j.neuron.2018.10.031
215.
Rogers J., Li R., Mastroeni D., Grover A., Leonard B., Ahern G., Cao P., Kolody H., Vedders L., Kolb W.P., et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol. Aging. 2006;27:1733-1739.
Not in our library10.1016/j.neurobiolaging.2005.09.043
216.
Andersson C.R., Falsig J., Stavenhagen J.B., Christensen S., Kartberg F., Rosenqvist N., Finsen B., Pedersen J.T. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes. Sci. Rep. 2019;9:4658.
Not in our library10.1038/s41598-019-41105-4
217.
Jin C.Y., Moon D.O., Lee K.J., Kim M.O., Lee J.D., Choi Y.H., Park Y.M., Kim G.Y. Piceatannol attenuates lipopolysaccharide-induced NF-kappaB activation and NF-kappaB-related proinflammatory mediators in BV2 microglia. Pharmacol. Res. 2006;54:461-467.
Not in our library10.1016/j.phrs.2006.09.005
218.
Song X., Shapiro S., Goldman D.L., Casadevall A., Scharff M., Lee S.C. Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microglia. Infect. Immun. 2002;70:5177-5184.
Not in our library10.1128/iai.70.9.5177-5184.2002
219.
Congdon E.E., Chukwu J.E., Shamir D.B., Deng J., Ujla D., Sait H.B.R., Neubert T.A., Kong X.P., Sigurdsson E.M. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. EBioMedicine. 2019;42:157-173.
Not in our library10.1016/j.ebiom.2019.03.033
220.
Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916-919.
Not in our library10.1038/78682
221.
Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003;23:3745-3751.
Not in our library10.1523/jneurosci.23-09-03745.2003
222.
Ittner A., Bertz J., Suh L.S., Stevens C.H., Gotz J., Ittner L.M. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J. Neurochem. 2015;132:135-145.
Not in our library10.1111/jnc.12821
223.
Lee S.H., Le Pichon C.E., Adolfsson O., Gafner V., Pihlgren M., Lin H., Solanoy H., Brendza R., Ngu H., Foreman O., et al. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Rep. 2016;16:1690-1700.
Not in our library10.1016/j.celrep.2016.06.099
224.
Vitale F., Giliberto L., Ruiz S., Steslow K., Marambaud P., d’Abramo C. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol. Commun. 2018;6:82.
Not in our library10.1186/s40478-018-0585-2
225.
Bornemann K.D., Wiederhold K.H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., Staufenbiel M. Aβ-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 2001;158:63-73.
Not in our library10.1016/s0002-9440(10)63945-4
226.
Chung H., Brazil M.I., Irizarry M.C., Hyman B.T., Maxfield F.R. Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. Neuroreport. 2001;12:1151-1154.
Not in our library10.1097/00001756-200105080-00020
227.
Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., El-Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 2002;160:101-112.
Not in our library10.1016/s0002-9440(10)64354-4
228.
El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., Freeman M.W., Luster A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 2003;197:1657-1666.
Not in our library10.1084/jem.20021546
229.
Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., Freeman M.W. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 2002;277:47373-47379.
Not in our library10.1074/jbc.m208788200
230.
Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010;11:155-161.
Not in our library10.1038/ni.1836
231.
Onyango I.G., Tuttle J.B., Bennett J.P. Altered intracellular signaling and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol. Cell. Neurosci. 2005;29:333-343.
Not in our library10.1016/j.mcn.2005.02.012
232.
Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907-913.
Not in our library10.1038/nm890
233.
Origlia N., Bonadonna C., Rosellini A., Leznik E., Arancio O., Yan S.S., Domenici L. Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J. Neurosci. 2010;30:11414-11425.
Not in our library10.1523/jneurosci.2127-10.2010
234.
The Receptor for Advanced Glycation End-Products (RAGE) Is Only Present in Mammals, and Belongs to a Family of Cell Adhesion Molecules (CAMs) · 2014
No notice
235.
Juranek J., Ray R., Banach M., Rai V. Receptor for advanced glycation end-products in neurodegenerative diseases. Rev. Neurosci. 2015;26:691-698.
Not in our library10.1515/revneuro-2015-0003
236.
Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., et al. RAGE and amyloid beta interactions: Atomic force microscopy and molecular modeling. Biochim. Biophys. Acta. 2005;1741:199-205.
Not in our library10.1016/j.bbadis.2005.03.014
237.
Yan S.S., Chen D., Yan S., Guo L., Du H., Chen J.X. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer’s disease. Front. Biosci. 2012;4:240-250.
Not in our library10.2741/s265
238.
Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., Walker D.G., Stern D.M., Yan S., Schmidt A.M., et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J. 2010;24:1043-1055.
Not in our library10.1096/fj.09-139634
239.
Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685-691.
Not in our library10.1038/382685a0
240.
Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Investig. 2012;122:1377-1392.
Not in our library10.1172/jci58642
241.
Park S.W., Kim J.H., Park S.M., Moon M., Lee K.H., Park K.H., Park W.J., Kim J.H. RAGE mediated intracellular Aβ uptake contributes to the breakdown of tight junction in retinal pigment epithelium. Oncotarget. 2015;6:35263-35273.
Not in our library10.18632/oncotarget.5894
242.
Zhou Y., Ulland T.K., Colonna M. TREM2-Dependent Effects on Microglia in Alzheimer’s Disease. Front. Aging Neurosci. 2018;10:202.
Not in our library10.3389/fnagi.2018.00202
243.
Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer’s disease. New Engl. J. Med. 2013;368:117-127.
Not in our library10.1056/nejmoa1211851
244.
Frank S., Burbach G.J., Bonin M., Walter M., Streit W., Bechmann I., Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438-1447.
Not in our library10.1002/glia.20710
245.
Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160:1061-1071.
Not in our library10.1016/j.cell.2015.01.049
246.
Jiang T., Wan Y., Zhang Y.D., Zhou J.S., Gao Q., Zhu X.C., Shi J.Q., Lu H., Tan L., Yu J.T. TREM2 Overexpression has No Improvement on Neuropathology and Cognitive Impairment in Aging APPswe/PS1dE9 Mice. Mol. Neurobiol. 2017;54:855-865.
Not in our library10.1007/s12035-016-9704-x
247.
Leyns C.E.G., Ulrich J.D., Finn M.B., Stewart F.R., Koscal L.J., Remolina Serrano J., Robinson G.O., Anderson E., Colonna M., Holtzman D.M. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. USA. 2017;114:11524-11529.
Not in our library10.1073/pnas.1710311114
248.
TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy · 2017
No notice
249.
Jay T.R., Hirsch A.M., Broihier M.L., Miller C.M., Neilson L.E., Ransohoff R.M., Lamb B.T., Landreth G.E. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer’s Disease. J. Neurosci. 2017;37:637-647.
Not in our library10.1523/jneurosci.2110-16.2016
250.
Jay T.R., Miller C.M., Cheng P.J., Graham L.C., Bemiller S., Broihier M.L., Xu G., Margevicius D., Karlo J.C., Sousa G.L., et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J. Exp. Med. 2015;212:287-295.
Not in our library10.1084/jem.20142322
251.
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 · 2014
No notice
252.
Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., Tanzi R.E. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631-643.
Not in our library10.1016/j.neuron.2013.04.014
253.
Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis · 2014
No notice
254.
TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease · 2011
No notice
255.
Current Views of Toll-Like Receptor Signaling Pathways · 2010
No notice
256.
Jana M., Palencia C.A., Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: Implications for Alzheimer’s disease. J. Immunol. 2008;181:7254-7262.
Not in our library10.4049/jimmunol.181.10.7254
257.
Walker D.G., Tang T.M., Lue L.F. Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer’s disease brains. Exp. Neurol. 2018;309:91-106.
Not in our library10.1016/j.expneurol.2018.07.016
258.
Delgado M.A., Elmaoued R.A., Davis A.S., Kyei G., Deretic V. Toll-like receptors control autophagy. EMBO J. 2008;27:1110-1121.
Not in our library10.1038/emboj.2008.31
259.
Anderson K.V. Toll signaling pathways in the innate immune response. Curr. Opin. Immunol. 2000;12:13-19.
Not in our library10.1016/s0952-7915(99)00045-x
260.
O’Neill L.A., Greene C. Signal transduction pathways activated by the IL-1 receptor family: Ancient signaling machinery in mammals, insects, and plants. J. Leukoc. Biol. 1998;63:650-657.
Not in our library10.1002/jlb.63.6.650
261.
Zhang G., Ghosh S. Toll-like receptor-mediated NF-kappaB activation: A phylogenetically conserved paradigm in innate immunity. J. Clin. Investig. 2001;107:13-19.
Not in our library10.1172/jci11837
262.
Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O’Loughlin E., Xu Y., Fanek Z., et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566-581.e9.
Not in our library10.1016/j.immuni.2017.08.008
263.
Konttinen H., Cabral-da-Silva M.E.C., Ohtonen S., Wojciechowski S., Shakirzyanova A., Caligola S., Giugno R., Ishchenko Y., Hernández D., Fazaludeen M.F., et al. PSEN1DeltaE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Rep. 2019;13:669-683.
Not in our library10.1016/j.stemcr.2019.08.004
264.
Prasad H., Rao R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proc. Natl. Acad. Sci. USA. 2018;115:E6640-E6649.
Not in our library10.1073/pnas.1801612115
265.
Shi Y., Manis M., Long J., Wang K., Sullivan P.M., Remolina Serrano J., Hoyle R., Holtzman D.M. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 2019;216:2546-2561.
Not in our library10.1084/jem.20190980
266.
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease · 2020
No notice
267.
Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523-527.
Not in our library10.1038/nature24016
268.
Lynch J.R., Tang W., Wang H., Vitek M.P., Bennett E.R., Sullivan P.M., Warner D.S., Laskowitz D.T. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 2003;278:48529-48533.
Not in our library10.1074/jbc.m306923200
269.
Zlokovic B.V. Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. JAMA Neurol. 2013;70:440-444.
Not in our library10.1001/jamaneurol.2013.2152
270.
Teng Z., Guo Z., Zhong J., Cheng C., Huang Z., Wu Y., Tang S., Luo C., Peng X., Wu H., et al. ApoE Influences the Blood-Brain Barrier Through the NF-kappaB/MMP-9 Pathway After Traumatic Brain Injury. Sci. Rep. 2017;7:6649.
Not in our library10.1038/s41598-017-06932-3
271.
Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512-516.
Not in our library10.1038/nature11087
272.
Du Y., Chen X., Wei X., Bales K.R., Berg D.T., Paul S.M., Farlow M.R., Maloney B., Ge Y.W., Lahiri D.K. NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res. Mol. Brain Res. 2005;136:177-188.
Not in our library10.1016/j.molbrainres.2005.02.001
273.
New insights into the role of TREM2 in Alzheimer’s disease · 2018
No notice
274.
Ennerfelt H.E., Lukens J.R. The role of innate immunity in Alzheimer’s disease. Immunol. Rev. 2020;297:225-246.
Not in our library10.1111/imr.12896
275.
Merino J.J., Muneton-Gomez V., Alvarez M.I., Toledano-Diaz A. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer’s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD? Curr. Alzheimer Res. 2016;13:403-412.
Not in our library10.2174/1567205013666151116125714
276.
Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., Huang D., Kidd G., Dombrowski S., Dutta R., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006;9:917-924.
Not in our library10.1038/nn1715
277.
Chen P., Zhao W., Guo Y., Xu J., Yin M. CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection. Biomed. Res. Int. 2016;2016:8090918.
Not in our library10.1155/2016/8090918
278.
Febinger H.Y., Thomasy H.E., Pavlova M.N., Ringgold K.M., Barf P.R., George A.M., Grillo J.N., Bachstetter A.D., Garcia J.A., Cardona A.E., et al. Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury. J. Neuroinflammation. 2015;12:154.
Not in our library10.1186/s12974-015-0386-5
279.
Cho S.H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011;286:32713-32722.
Not in our library10.1074/jbc.m111.254268
280.
Bhaskar K., Konerth M., Kokiko-Cochran O.N., Cardona A., Ransohoff R.M., Lamb B.T. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68:19-31.
Not in our library10.1016/j.neuron.2010.08.023
281.
Sellner S., Paricio-Montesinos R., Spiess A., Masuch A., Erny D., Harsan L.A., Elverfeldt D.V., Schwabenland M., Biber K., Staszewski O., et al. Microglial CX3CR1 promotes adult neurogenesis by inhibiting Sirt 1/p65 signaling independent of CX3CL1. Acta Neuropathol. Commun. 2016;4:102.
Not in our library10.1186/s40478-016-0374-8
282.
Nash B., Meucci O. Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors. Int. Rev. Neurobiol. 2014;118:105-128.
Not in our library10.1016/b978-0-12-801284-0.00005-1
283.
Mao W., Yi X., Qin J., Tian M., Jin G. CXCL12 promotes proliferation of radial glia like cells after traumatic brain injury in rats. Cytokine. 2020;125:154771.
Not in our library10.1016/j.cyto.2019.154771
284.
Mao W., Yi X., Qin J., Tian M., Jin G. CXCL12/CXCR4 Axis Improves Migration of Neuroblasts Along Corpus Callosum by Stimulating MMP-2 Secretion After Traumatic Brain Injury in Rats. Neurochem. Res. 2016;41:1315-1322.
Not in our library10.1007/s11064-016-1831-2
285.
Sanfilippo C., Castrogiovanni P., Imbesi R., Nunnari G., Di Rosa M. Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels. Brain Res. 2020;1749:147127.
Not in our library10.1016/j.brainres.2020.147127
286.
Bianchi M.E. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 2007;81:1-5.
Not in our library10.1189/jlb.0306164
287.
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting · 2020
No notice
288.
Chikhirzhina E., Starkova T., Beljajev A., Polyanichko A., Tomilin A. Functional Diversity of Non-Histone Chromosomal Protein HmgB1. Int. J. Mol. Sci. 2020;21:7948.
Not in our library10.3390/ijms21217948
289.
Vande Walle L., Kanneganti T.-D., Lamkanfi M. HMGB1 release by inflammasomes. Virulence. 2011;2:162-165.
Not in our library10.4161/viru.2.2.15480
290.
Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010;28:367-388.
Not in our library10.1146/annurev.immunol.021908.132603
291.
Indirect regulation of HMGB1 release by gasdermin D · 2020
No notice
292.
Nan K., Han Y., Fang Q., Huang C., Yu L., Ge W., Xiang F., Tao Y.X., Cao H., Li J. HMGB1 gene silencing inhibits neuroinflammation via down-regulation of NF-κB signaling in primary hippocampal neurons induced by Aβ(25-35). Int. Immunopharmacol. 2019;67:294-301.
Not in our library10.1016/j.intimp.2018.12.027
293.
Falcão A.S., Carvalho L.A., Lidónio G., Vaz A.R., Lucas S.D., Moreira R., Brites D. Dipeptidyl Vinyl Sulfone as a Novel Chemical Tool to Inhibit HMGB1/NLRP3-Inflammasome and Inflamma-miRs in Aβ-Mediated Microglial Inflammation. ACS Chem. Neurosci. 2017;8:89-99.
Not in our library10.1021/acschemneuro.6b00250
294.
Takata K., Takada T., Ito A., Asai M., Tawa M., Saito Y., Ashihara E., Tomimoto H., Kitamura Y., Shimohama S. Microglial Amyloid-β1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer’s Disease. Int. J. Alzheimer’s Dis. 2012;2012:685739.
Not in our library10.1155/2012/685739
295.
HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction · 2018
No notice
296.
HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer’s disease · 2016
No notice
297.
S100 Proteins in Alzheimer’s Disease · 2019
No notice
298.
Mrak R.E., Griffinbc W.S. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol. Aging. 2001;22:915-922.
Not in our library10.1016/s0197-4580(01)00293-7
299.
Sen J., Belli A. S100B in neuropathologic states: The CRP of the brain? J. Neurosci. Res. 2007;85:1373-1380.
Not in our library10.1002/jnr.21211
300.
Serum levels of S100B and NSE proteins in Alzheimer's disease patients · 2010
No notice
301.
Bianchi R., Kastrisianaki E., Giambanco I., Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J. Biol. Chem. 2011;286:7214-7226.
Not in our library10.1074/jbc.m110.169342
302.
S100B Protein, a Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond · 2010
No notice
303.
Bianchi R., Giambanco I., Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging. 2010;31:665-677.
Not in our library10.1016/j.neurobiolaging.2008.05.017
304.
Shen L., Liao L., Chen C., Guo Y., Song D., Wang Y., Chen Y., Zhang K., Ying M., Li S., et al. Proteomics Analysis of Blood Serums from Alzheimer’s Disease Patients Using iTRAQ Labeling Technology. J. Alzheimer’s Dis. 2017;56:361-378.
Not in our library10.3233/jad-160913
305.
Kummer M.P., Vogl T., Axt D., Griep A., Vieira-Saecker A., Jessen F., Gelpi E., Roth J., Heneka M.T. Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. J. Neurosci. 2012;32:17824-17829.
Not in our library10.1523/jneurosci.1504-12.2012
306.
Ma L., Sun P., Zhang J.-C., Zhang Q., Yao S.-L. Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells. Int. J. Mol. Med. 2017;40:31-38.
Not in our library10.3892/ijmm.2017.2987
307.
Lodeiro M., Puerta E., Ismail M.A., Rodriguez-Rodriguez P., Rönnbäck A., Codita A., Parrado-Fernandez C., Maioli S., Gil-Bea F., Merino-Serrais P., et al. Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions. J. Gerontol. A Biol. Sci. Med. Sci. 2017;72:319-328.
Not in our library10.1093/gerona/glw073
308.
Walker D.G., Link J., Lue L.F., Dalsing-Hernandez J.E., Boyes B.E. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J. Leukoc. Biol. 2006;79:596-610.
Not in our library10.1189/jlb.0705377
309.
Iashchishyn I.A., Sulskis D., Nguyen Ngoc M., Smirnovas V., Morozova-Roche L.A. Finke-Watzky Two-Step Nucleation-Autocatalysis Model of S100A9 Amyloid Formation: Protein Misfolding as “Nucleation” Event. ACS Chem. Neurosci. 2017;8:2152-2158.
Not in our library10.1021/acschemneuro.7b00251
310.
Gruden M.A., Davydova T.V., Kudrin V.S., Wang C., Narkevich V.B., Morozova-Roche L.A., Sewell R.D.E. S100A9 Protein Aggregates Boost Hippocampal Glutamate Modifying Monoaminergic Neurochemistry: A Glutamate Antibody Sensitive Outcome on Alzheimer-like Memory Decline. ACS Chem. Neurosci. 2018;9:568-577.
Not in our library10.1021/acschemneuro.7b00379
311.
Wang C., Iashchishyn I.A., Pansieri J., Nyström S., Klementieva O., Kara J., Horvath I., Moskalenko R., Rofougaran R., Gouras G., et al. S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimer’s Disease. Sci. Rep. 2018;8:12836.
Not in our library10.1038/s41598-018-31141-x
312.
Chang K.A., Kim H.J., Suh Y.H. The role of S100a9 in the pathogenesis of Alzheimer’s disease: The therapeutic effects of S100a9 knockdown or knockout. Neurodegener. Dis. 2012;10:27-29.
Not in our library10.1159/000333781
313.
Autophagy and inflammation · 2017
No notice
314.
Torre D., Speranza F., Giola M., Matteelli A., Tambini R., Biondi G. Role of Th1 and Th2 Cytokines in Immune Response to Uncomplicated Plasmodium falciparum Malaria. Clin. Diagn. Lab. Immunol. 2002;9:348-351.
Not in our library10.1128/cdli.9.2.348-351.2002
315.
Wu T.T., Li W.M., Yao Y.M. Interactions between Autophagy and Inhibitory Cytokines. Int. J. Biol. Sci. 2016;12:884-897.
Not in our library10.7150/ijbs.15194
316.
Harris J., Hartman M., Roche C., Zeng S.G., O’Shea A., Sharp F.A., Lambe E.M., Creagh E.M., Golenbock D.T., Tschopp J., et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J. Biol. Chem. 2011;286:9587-9597.
Not in our library10.1074/jbc.m110.202911
317.
Mitochondrial Dysfunction and Alzheimer’s Disease: Role of Microglia · 2020
No notice
318.
Wu A.-G., Zhou X.-G., Qiao G., Yu L., Tang Y., Yan L., Qiu W.-Q., Pan R., Yu C.-L., Law B.Y.-K., et al. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Ageing Res. Rev. 2021;65:101202.
Not in our library10.1016/j.arr.2020.101202
319.
Banati R., Gehrmann J., Kellner M., Holsboer F. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin. Neuropathol. 1995;14:197-200.
Not in our library
320.
Pomilio C., Gorojod R.M., Riudavets M., Vinuesa A., Presa J., Gregosa A., Bentivegna M., Alaimo A., Alcon S.P., Sevlever G., et al. Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: Evidence from experimental models and Alzheimer’s disease patients. Geroscience. 2020;42:613-632.
Not in our library10.1007/s11357-020-00161-9
321.
Jia R., Guardia C.M., Pu J., Chen Y., Bonifacino J.S. BORC coordinates encounter and fusion of lysosomes with autophagosomes. Autophagy. 2017;13:1648-1663.
Not in our library10.1080/15548627.2017.1343768
322.
Stoka V., Turk V., Turk B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res. Rev. 2016;32:22-37.
Not in our library10.1016/j.arr.2016.04.010
323.
A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration · 2018
No notice
324.
Sun Q., Fan J., Billiar T.R., Scott M.J. Inflammasome and autophagy regulation: A two-way street. Mol. Med. 2017;23:188-195.
Not in our library10.2119/molmed.2017.00077
325.
Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications · 2018
No notice
326.
Hansen D.V., Hanson J.E., Sheng M. Microglia in Alzheimer’s disease. J. Cell Biol. 2018;217:459-472.
Not in our library10.1083/jcb.201709069
327.
Machado V., Zöller T., Attaai A., Spittau B. Microglia-mediated neuroinflammation and neurotrophic factor-induced protection in the MPTP mouse model of Parkinson’s disease-lessons from transgenic mice. Int. J. Mol. Sci. 2016;17:151.
Not in our library10.3390/ijms17020151
328.
Wang W.-Y., Tan M.-S., Yu J.-T., Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann. Transl. Med. 2015;3.
Not in our library10.3978/j.issn.2305-5839.2015.03.49
329.
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease · 2018
No notice
330.
Phagocytosis of Microglia in the Central Nervous System Diseases · 2014
No notice
331.
Lucin K.M., O’Brien C.E., Bieri G., Czirr E., Mosher K.I., Abbey R.J., Mastroeni D.F., Rogers J., Spencer B., Masliah E., et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron. 2013;79:873-886.
Not in our library10.1016/j.neuron.2013.06.046
332.
Lee J.-W., Nam H., Kim L.E., Jeon Y., Min H., Ha S., Lee Y., Kim S.-Y., Lee S.J., Kim E.-K. TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia. Autophagy. 2019;15:753-770.
Not in our library10.1080/15548627.2018.1556946
333.
Martinez J., Almendinger J., Oberst A., Ness R., Dillon C.P., Fitzgerald P., Hengartner M.O., Green D.R. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc. Natl. Acad. Sci. USA. 2011;108:17396-17401.
Not in our library10.1073/pnas.1113421108
334.
Sanjuan M.A., Dillon C.P., Tait S.W., Moshiach S., Dorsey F., Connell S., Komatsu M., Tanaka K., Cleveland J.L., Withoff S., et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature. 2007;450:1253-1257.
Not in our library10.1038/nature06421
335.
Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging · 2017
No notice
336.
Etchegaray J.I., Elguero E.J., Tran J.A., Sinatra V., Feany M.B., McCall K. Defective phagocytic corpse processing results in neurodegeneration and can be rescued by TORC1 activation. J. Neurosci. 2016;36:3170-3183.
Not in our library10.1523/jneurosci.1912-15.2016
337.
Houtman J., Freitag K., Gimber N., Schmoranzer J., Heppner F.L., Jendrach M. Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3. EMBO J. 2019;38:e99430.
Not in our library10.15252/embj.201899430
338.
Su P., Zhang J., Wang D., Zhao F., Cao Z., Aschner M., Luo W. The role of autophagy in modulation of neuroinflammation in microglia. Neuroscience. 2016;319:155-167.
Not in our library10.1016/j.neuroscience.2016.01.035
339.
De Biase D., Piegari G., Prisco F., Cimmino I., Pirozzi C., Mattace Raso G., Oriente F., Grieco E., Papparella S., Paciello O. Autophagy and NLRP3 inflammasome crosstalk in neuroinflammation in aged bovine brains. J. Cell. Physiol. 2020;235:5394-5403.
Not in our library10.1002/jcp.29426
340.
Bussi C., Peralta Ramos J.M., Arroyo D.S., Gaviglio E.A., Gallea J.I., Wang J.M., Celej M.S., Iribarren P. Autophagy down regulates pro-inflammatory mediators in BV2 microglial cells and rescues both LPS and alpha-synuclein induced neuronal cell death. Sci. Rep. 2017;7:43153.
Not in our library10.1038/srep43153
341.
Xu T., Jiang L., Wang Z. The progression of HMGB1-induced autophagy in cancer biology. OncoTargets Ther. 2018;12:365-377.
Not in our library10.2147/ott.s185876
342.
Ghavami S., Eshragi M., Ande S.R., Chazin W.J., Klonisch T., Halayko A.J., McNeill K.D., Hashemi M., Kerkhoff C., Los M. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res. 2010;20:314-331.
Not in our library10.1038/cr.2009.129
343.
King B.C., Kulak K., Colineau L., Blom A.M. Outside in: Roles of complement in autophagy. Br. J. Pharmacol. 2020;1-16.
Not in our library10.1111/bph.15192
344.
Vernon P.J., Tang D. Eat-me: Autophagy, phagocytosis, and reactive oxygen species signaling. Antioxid. Redox Signal. 2013;18:677-691.
Not in our library10.1089/ars.2012.4810
345.
Yang L., Geng T., Yang G., Ma J., Wang L., Ketkar H., Yang D., Lin T., Hwang J., Zhu S., et al. Macrophage scavenger receptor 1 controls Chikungunya virus infection through autophagy in mice. Commun. Biol. 2020;3:556.
Not in our library10.1038/s42003-020-01285-6
346.
Kang R., Tang D., Schapiro N.E., Livesey K.M., Farkas A., Loughran P., Bierhaus A., Lotze M.T., Zeh H.J. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010;17:666-676.
Not in our library10.1038/cdd.2009.149
347.
Hu X., Mei S., Meng W., Xue S., Jiang L., Yang Y., Hui L., Chen Y., Guan M.X. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance. Cancer Lett. 2018;425:1-12.
Not in our library10.1016/j.canlet.2018.03.024
348.
Role of Toll Like Receptor 4 in Alzheimer’s Disease · 2020
No notice
349.
Qin Y., Liu Y., Hao W., Decker Y., Tomic I., Menger M.D., Liu C., Fassbender K. Stimulation of TLR4 Attenuates Alzheimer’s Disease-Related Symptoms and Pathology in Tau-Transgenic Mice. J. Immunol. 2016;197:3281-3292.
Not in our library10.4049/jimmunol.1600873
350.
Liu S., Liu Y., Hao W., Wolf L., Kiliaan A.J., Penke B., Rübe C.E., Walter J., Heneka M.T., Hartmann T., et al. TLR2 is a primary receptor for Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J. Immunol. 2012;188:1098-1107.
Not in our library10.4049/jimmunol.1101121
351.
Arroyo D.S., Soria J.A., Gaviglio E.A., Garcia-Keller C., Cancela L.M., Rodriguez-Galan M.C., Wang J.M., Iribarren P. Toll-like receptor 2 ligands promote microglial cell death by inducing autophagy. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2013;27:299-312.
Not in our library10.1096/fj.12-214312
352.
François A., Rioux Bilan A., Quellard N., Fernandez B., Janet T., Chassaing D., Paccalin M., Terro F., Page G. Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice. J. Neuroinflammation. 2014;11:139.
Not in our library10.1186/s12974-014-0139-x
353.
Simonovitch S., Schmukler E., Bespalko A., Iram T., Frenkel D., Holtzman D.M., Masliah E., Michaelson D.M., Pinkas-Kramarski R. Impaired Autophagy in APOE4 Astrocytes. J. Alzheimer’s Dis. 2016;51:915-927.
Not in our library10.3233/jad-151101
354.
Parcon P.A., Balasubramaniam M., Ayyadevara S., Jones R.A., Liu L., Shmookler Reis R.J., Barger S.W., Mrak R.E., Griffin W.S.T. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2018;14:230-242.
Not in our library10.1016/j.jalz.2017.07.754
355.
Su S.-H., Wu Y.-F., Lin Q., Wang D.-P., Hai J. URB597 protects against NLRP3 inflammasome activation by inhibiting autophagy dysfunction in a rat model of chronic cerebral hypoperfusion. J. Neuroinflammation. 2019;16:1-15.
Not in our library10.1186/s12974-019-1668-0
356.
Zhang Y., Sauler M., Shinn A.S., Gong H., Haslip M., Shan P., Mannam P., Lee P.J. Endothelial PINK1 mediates the protective effects of NLRP3 deficiency during lethal oxidant injury. J. Immunol. 2014;192:5296-5304.
Not in our library10.4049/jimmunol.1400653
357.
Archibald J.M. Endosymbiosis and Eukaryotic Cell Evolution. Curr. Biol. 2015;25:R911-R921.
Not in our library10.1016/j.cub.2015.07.055
358.
Mitochondria: An Organelle of Bacterial Origin Controlling Inflammation · 2018
No notice
359.
Contis A., Mitrovic S., Lavie J., Douchet I., Lazaro E., Truchetet M.E., Goizet C., Contin-Bordes C., Schaeverbeke T., Blanco P., et al. Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritis. Rheumatology. 2017;56:1200-1205.
Not in our library10.1093/rheumatology/kex041
360.
West A.P., Khoury-Hanold W., Staron M., Tal M.C., Pineda C.M., Lang S.M., Bestwick M., Duguay B.A., Raimundo N., MacDuff D.A., et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553-557.
Not in our library10.1038/nature14156
361.
Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104-107.
Not in our library10.1038/nature08780
362.
Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401-414.
Not in our library10.1016/j.immuni.2012.01.009
363.
Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., Englert J.A., Rabinovitch M., Cernadas M., Kim H.P., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011;12:222-230.
Not in our library10.1038/ni.1980
364.
Naviaux R.K. Metabolic features of the cell danger response. Mitochondrion. 2014;16:7-17.
Not in our library10.1016/j.mito.2013.08.006
365.
Iyer S.S., Pulskens W.P., Sadler J.J., Butter L.M., Teske G.J., Ulland T.K., Eisenbarth S.C., Florquin S., Flavell R.A., Leemans J.C., et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. USA. 2009;106:20388-20393.
Not in our library10.1073/pnas.0908698106
366.
Iyer S.S., He Q., Janczy J.R., Elliott E.I., Zhong Z., Olivier A.K., Sadler J.J., Knepper-Adrian V., Han R., Qiao L., et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity. 2013;39:311-323.
Not in our library10.1016/j.immuni.2013.08.001
367.
Raoof M., Zhang Q., Itagaki K., Hauser C.J. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J. Trauma. 2010;68:1328-1334.
Not in our library10.1097/ta.0b013e3181dcd28d
368.
Castanier C., Garcin D., Vazquez A., Arnoult D. Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway. EMBO Rep. 2010;11:133-138.
Not in our library10.1038/embor.2009.258
369.
Tal M.C., Sasai M., Lee H.K., Yordy B., Shadel G.S., Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc. Natl. Acad. Sci. USA. 2009;106:2770-2775.
Not in our library10.1073/pnas.0807694106
370.
Nobre L., Wise D., Ron D., Volmer R. Modulation of Innate Immune Signalling by Lipid-Mediated MAVS Transmembrane Domain Oligomerization. PLoS ONE. 2015;10:e0136883.
Not in our library10.1371/journal.pone.0136883
371.
Meyer A., Laverny G., Allenbach Y., Grelet E., Ueberschlag V., Echaniz-Laguna A., Lannes B., Alsaleh G., Charles A.L., Singh F., et al. IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol. 2017;134:655-666.
Not in our library10.1007/s00401-017-1731-9
372.
Roy E.R., Wang B., Wan Y.-W., Chiu G., Cole A., Yin Z., Propson N.E., Xu Y., Jankowsky J.L., Liu Z., et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J. Clin. Investig. 2020;130:1912-1930.
Not in our library10.1172/jci133737
373.
Zhong B., Yang Y., Li S., Wang Y.Y., Li Y., Diao F., Lei C., He X., Zhang L., Tien P., et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008;29:538-550.
Not in our library10.1016/j.immuni.2008.09.003
374.
Zhong B., Zhang L., Lei C., Li Y., Mao A.P., Yang Y., Zhang X.L., Shu H.B. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity. 2009;30:397-407.
Not in our library10.1016/j.immuni.2009.01.008
375.
Ye J., Jiang Z., Chen X., Liu M., Li J., Liu N. The role of autophagy in pro-inflammatory responses of microglia activation via mitochondrial reactive oxygen species in vitro. J. Neurochem. 2017;142:215-230.
Not in our library10.1111/jnc.14042
376.
Wu J., Li X., Zhu G., Zhang Y., He M., Zhang J. The role of Resveratrol-induced mitophagy/autophagy in peritoneal mesothelial cells inflammatory injury via NLRP3 inflammasome activation triggered by mitochondrial ROS. Exp. Cell Res. 2016;341:42-53.
Not in our library10.1016/j.yexcr.2016.01.014
377.
Thangaraj A., Periyasamy P., Guo M.-L., Chivero E.T., Callen S., Buch S. Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics. Autophagy. 2020;16:289-312.
Not in our library10.1080/15548627.2019.1607686
378.
Lei Q., Tan J., Yi S., Wu N., Wang Y., Wu H. Mitochonic acid 5 activates the MAPK–ERK–yap signaling pathways to protect mouse microglial BV-2 cells against TNFα-induced apoptosis via increased Bnip3-related mitophagy. Cell. Mol. Biol. Lett. 2018;23:1-16.
Not in our library10.1186/s11658-018-0081-5
379.
Gao A., Jiang J., Xie F., Chen L. Bnip3 in mitophagy: Novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction. Clin. Chim. Acta. 2020;506:72-83.
Not in our library10.1016/j.cca.2020.02.024
380.
He Y.-L., Gong S.-H., Cheng X., Zhao M., Zhao T., Zhao Y.-Q., Fan M., Zhu L.L., Wu L.Y. BNIP3 phosphorylation by JNK1/2 promotes mitophagy via enhancing its stability under hypoxia. bioRxiv. 2020.
Not in our library10.1101/2020.08.27.271270
381.
Activation of BNIP3-mediated mitophagy protects against renal ischemia–reperfusion injury · 2019
No notice
382.
Clinical trials of new drugs for Alzheimer disease · 2020
No notice
383.
Lautrup S., Lou G., Aman Y., Nilsen H., Tao J., Fang E.F. Microglial mitophagy mitigates neuroinflammation in Alzheimer’s disease. Neurochem. Int. 2019;129:104469.
Not in our library10.1016/j.neuint.2019.104469

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.